Issuu on Google+

1-15 July 2012 I Vol 1 I No 1 I `100

Scan this code on your smart phone to visit www.mphonline.in

CEO Roundtable 15

In Conversation With 17

Special Focus 18

Insight & Outlook 22

Future trends in the Indian pharma industry and the role of media to bridge the need gap

Indravadan Modi Chairman, Cadila Pharmaceuticals Ltd

Recent advances in the pharma cold chain The need to get tech-savvy

Sales force automation Say ‘no’ to manual errors

Venus gets US patent for antibiotic drug VENUS Remedies has received patent from the US Patent Office for its new antibiotic product, which targets drug resistant infections. The product, CSE 1034, has been found to be effective against a wide range of drug resistant infections, including the ‘superbugs’. Mufti Suhail Sayeed, Vice Sayeed President, Venus Medical Research Centre, said, “The US patent of CSE 1034 is a landmark development for initiating the process of commercialisation of this novel drug.”

Alembic settles patent case with Novartis ALEMBIC Pharmaceuticals along with Breckenridge Pharmaceutical (US), has settled a patent case with Novartis for rivastigmine tartrate capsules used for treating dementia. The companies have settled their Paragraph IV patent litigation with Novartis for rivastigmine tartrate capsules, a generic version of Exelon capsules of Novartis.

Positive prospects for Japanese pharma industry THE prospects for Japan’s pharma market over the medium term are very positive, said a report by Research and Markets. The country has one of the largest pensionable populations, healthcare is readily accessible, the government appreciates investment in biomedical research and the regulatory regime balances the requirements of the major stakeholders.

GSK to buy eczema drug Toctino for £ 146 million GLAXOSMITHKLINE Plc (GSK) hasannounced that it is buying eczema drug Toctino from Basilea Pharmaceutica Ltd, for an initial £ 146 million ($ 227 million). Toctino is the only prescription medicine approved for the treatment of severe chronic hand eczema unresponsive to potent topical steroids in adults. It is commercially available in 14 countries, approved in 15 countries, and is in a phase III trial in the US.

Waters to expand in India WATERS India, one of the leading analytical companies is currently under the process of expanding its facility in Bengaluru. “The new facility is likely to have an improved set of laboratories, upgraded training facilities and more office space. When completed, the new facility will be approximately 16,000 square feet in floor space,” informed Art Caputo, President, Waters Division, Waters Inc. To expand the existing facility at Peenya, Bengaluru, the company has invested an approximate amount of ` 2 million. Besides this, the labs in Mumbai, Delhi and Hyderabad will also undergo an expansion in

the near future. The phase II of expansion woould be at Ahmedabad and Chandigarh. Besides expansion Waters is also partnering with pharmaceutical companies, CROs and government agencies with the goal of expanding research capabilities, increasing laboratory efficiency, and navigating complex regulatory compliance requirements worldwide. Waters has recent partnered with Dr Reddy’s Laboratories, Lambda Therapeutic Research Ltd, the Marine/ Agricultural Product Export Development Agency and the India Environmental Protection Agency.

Caputo

- Jasleen Kaur Batra

Ireland attracts Indian pharma FOR pharmaceuticals, the EU market is going through an inflection point. MNCs such as MSD, Johnson & Johnson, Pfizer, Abbott, Lilly, Roche, Novartis, Teva, Takeda, Genzyme, Allergan, Gilead, Astellas, Bristol-Myers Squibb and GlaxoSmithKline have established their foothold in Ireland. Besides, Indian companies such as Reliance Life Sciences and Ranbaxy have a strong presence too. K V Subramaniam, President and CEO, Reliance Life Sciences, said, “Reliance Life Sciences Pvt Ltd, India, had acquired GeneMedix plc, a UK-based biotechnology company in 2007. This provided us with an opportunity to enter the European biopharma market.” Minakshi Batra, India Director, IDA Ireland, said, “Each country in

the EU region has typical characteristics of operating. Germany is a tenderdriven, whereas France is an innovators drugdriven market. With such a background, it becomes absolutely essential for

small manufacturing base, could help in achieving radical benefits in terms of expediting go-to-market strategy by 40 per cent, reducing costs of inventory.” The Irish life sciences sector is about 45 billion

Subramaniam

Batra

Indian pharma companies to have an on-ground EU presence in order to expand into the EU territories. An on-ground presence either in terms of sales and marketing or a

(mainly export oriented). While the EU pharma market is worth $ 48 billion, $ 16 billion is for the generics, presenting huge opportunities for India. Batra said, “The

Irish Government is highly proactive, business friendly and an astute visionary. Ireland has some of the best highly skilled talent. It has a standard, EU approved corporation tax rate of 12.5 per cent on all trading profits. Additionally, Ireland has an excellent network of double taxation avoidance treaty with 55 countries in the world including India. Recognising this, the Irish Government has put in place a national Strategy for Science, Technology and Innovation (SSTI) in the 1990s. In line with this, significant funding and support are available to fuel innovation across industry, research and education. Additionally, there is a 25 per cent tax credit provided to organisations for R&D & innovation.” - Chandreyee Bhaumik

Quintiles deepens investment in China QUINTILES recently announced agreements to establish a Quintiles regional headquarters for China in Shanghai and to significantly expand lab testing capabilities in China. “With its burgeoning economy and growing healthcare needs for its 1.3 billion citizens, China exemplifies the opportunities and challenges

of the New Health,” said Dennis Gillings, CBE, Executive Chairman, Quintiles, “By broadening our investment and infrastructure here, Quintiles is ready to partner with our biopharma customers as they look to realise China’s potential.” To provide the infrastructure essential for its growth strategy

in China, Quintiles is investing $ 14 million to establish a new 4000-square-metre (43,000 square feet) headquarters in Shanghai to serve China and nearby Asian countries. “This demonstrates our commitment to this district and to China,” said Ling Zhen, General Manager, Quintiles’ operations in China.


Modern Pharma•1-15 July 2012

4

Editorial

Forthright and fortnight warm welcome to the first fortnightly edition of Modern Pharma (MPh)! It is a big moment for all of us – our discerning readers, our market savvy business associates, our visionary guides in the industry and of course the Team MPh, who has been zealously putting all the efforts together to embark on this new sojourn.

A

Editorial Advisory Board

A flashback of our service to the pharma industry over these years brings forward a mixed bag of feelings – of elation, introspection and the latest challenge of reaching out every fortnight with even more insightful as well as actionable information. Before moving onto further details, I intend to pause for a moment and express my deepest appreciation to you all, for making this wonderfully fast paced journey so thrilling and helping us become one the leading media platforms for the pharma industry in India.

Ajit Singh Chairman, ACG Worldwide & Head, ISPE

Dr Abraham Patani Past President, IDMA & CMD, Inga Laboratories

Dr Gopakumar G Nair IPR Consultant & Advisor

Dilip G Shah Chairman, IGPA & Secretary General, IPA

Daara Patel Secretary General, IDMA

Modern Pharma in this new avatar is bringing you a 3600 perspective on pharma value-chain cutting across business boundaries twice every month. This is being driven by news round-ups and multi-dimensional analysis thereof along with clear and actionable take-aways. In short, there are enough and more business enabling messages, which go far beyond stating the obvious, and reflect the following 4Ss: Simplified, straight, succinct and strategic.

Furthermore, Special Focus and Insight & Outlook sections will provide immense editorial value-adds every fortnight in terms of highly topical & incisive features along with brand new page layout as well as innovative design elements. In fact, the list is long enough to go beyond this space. Exciting times lie ahead for the Indian pharma industry with a recent McKinsey report projecting its total turnover to be more than double from now and reach $ 55 billion by 2020. However, there are numerous challenges on the way before we arrive at this destination. What can be a better way than to have some of the movers and shakers of the industry to share their expert views in this regard? Turn to the CEO Roundtable, exclusively organised by Modern Pharma, for some in-depth observations. All these promise many more market insights and business opportunities, and we will continue to empower you for better decision-making. Of course, you can expect our best possible service and nothing less. At the same time, we welcome your valuable feedback, suggestions, etc. Here’s to a refreshingly new journey with Modern Pharma!

Manas R Bastia manas@infomedia18.in

Guest Editorial

Egos risk a strategic sector he issue of screening Foreign Direct Investment (FDI) in the domestic pharmaceutical companies has ruffled egos in the PMO. The PMO has not taken kindly to the Commerce Minister and the Health Ministers’ persistence for preserving a strategic sector. Their effort is perceived as defiance of its authority. It has therefore asked compliance with October 2011 decision of leaving the screening of M&As of domestic companies by the foreign companies to the Competition Commission of India (CCI). In the meantime, the Department of Economic Affairs has constituted an eight-member Special Group (SG) for ‘streamlining the process for approval of FDI in brownfield pharma through FIPB’.

T

The differences between the PMO and the cabinet ministers and within the SG have clouded the thinking and the clarity of purpose. Both are missing the point: Should India preserve a strategic sector and develop indigenous R&D and manufacturing capabilities or let the MNCs dominate the Indian market as they have done in the rest of the world? It is well known that wherever MNCs have a strong presence, the domestic sector does not develop. Be it Brazil, South Africa or Thailand. India is an exception. Its journey began in the late 1960s when multinational corporations dilly-dallied

setting up local production and refused even to sell technical knowhow to the government. Instead, they continued to import finished dosage forms and sell at prices, which very few could afford. This is well documented in the Hathi Committee Report of 1975. Late Indira Gandhi realised the importance of this vital sector when India could not get enough medicines to treat its soldiers wounded in the war. She retaliated by abolishing product patent for pharmaceutical and encouraged policies that favoured domestic companies to setup local production from the basic stage. It took the country some 25 years to develop the domestic sector and capture dominant position. The MNCs’ share of the domestic market was reduced from about 85 per cent in 1970 to just 15 per cent in 1995. The next decade (1995-2005) witnessed onslaught of the domestic companies in the regulated markets of North America and Europe. Their safe, effective and quality products at prices that MNCs could not match helped them penetrate new markets, not only in the developing countries, but also in the backyards of the MNCs. As the domestic companies started hurting their commercial interests, the MNCs retaliated by introducing the International Medical Products AntiCounterfeiting Taskforce (IMPACT) in the WHO; by pushing for Patent Law Treaty (PLT) and Substantive Patent Law Treaty (SPLT) in the WIPO; by initiating

the Anti-Counterfeiting Trade Agreement (ACTA) and the Trans-Pacific Partnership (TPP) Agreement outside the multilateral fora and by pressurising the developing countries in signing the bilateral FTAs. They even prompted seizures of medicines in transit to browbeat the domestic companies. However, the government, aided by the civil society, fought back and thwarted their efforts. The acquisition of domestic companies is to be seen in this context. If only the egos had not come in the way, it would have been relatively easy to see through the purpose of acquisitions (if you can’t beat them, buy them) of jewels of the domestic sector and fine tune its response to save a vital sector of strategic import. It is yet not too late. India can allow through automatic route 100 per cent FDI in greenfield projects that bring in technical knowhow, invest in manufacturing of APIs from the basic stage and set up R&D labs. However, any investment in the existing domestic companies can either be capped like other strategic sectors such as aviation, banking, insurance, etc or filtered through a transparent process by the FIBP as being done for many other sectors. It must be realised that the CCI is not equipped to filter these acquisitions. D G Shah Secretary General, Indian Pharmaceutical Alliance (IPA)


Modern Pharma•1-15 July 2012

CONTENTS CEO Roundtable

15

15

Future trends in the Indian pharma industry and the role of media to bridge the need gap

In Conversation With

17

Indravadan Modi Chairman, Cadila Pharmaceuticals Ltd

Special Focus Pharma Logistics Recent advances in the pharma cold chain The need to get tech-savvy

18

Investments in SCM Is it adequate enough?

19

Interface

20

18

Ravi Kannan

22

CEO, Snowman Logistics Pvt Ltd

17

21

Roundtable Is there a need for SCM standards for transporting dry pharmaceuticals?

Facility Visit

FOUNDER & EDITOR, NETWORK 18 Raghav Bahl

22

SENIOR EDITOR Manas R Bastia FEATURES EDITOR Arshia Khan

Arshiya International FTWZ, Panvel Caring for the people and environment

Insight & Outlook: Automation Trends

PRESIDENT & EDITORIAL DIRECTOR, TV 18 Senthil Chengalvarayan

EDITORIAL TEAM Chandreyee Bhaumik, Parita Dholakia, Shibani Shah, Hemantraj Ratnakumar, Jasleen Kaur Batra (Bengaluru) ASSISTANT ART DIRECTOR Varuna Naik

23

Sales force automation Say ‘No’ to manual errors

DESIGN Sachin Bhogate CHIEF PHOTOGRAPHER Mexy Xavier PHOTOGRAPHY Neha Mithbawkar, Joshua Navalkar BUSINESS CONTROLLERS Surekha Karmarkar, Lovey Fernandes, Akshata Rane, Deepak Bhatia, Ashish Kukreti, Shwetha ME, Jayashree N, Sugandha Kulkarni, Shefali Mahant

PRINTING

Event Report

25

Cool Logistics Summit Cashing in on the growth opportunity in Indian pharma

EXECUTIVE VICE PRESIDENT Ananth R Iyer ASSISTANT GENERAL MANAGER - PPC Shekhar Khot

PRODUCTION TEAM Dnyaneshwar Goythale, Surekha Karmarkar, Ravikumar Potdar, Ravi Salian, Sanjay Shelar

OVERSEAS CONTACT Ringier Trade Media Ltd

REGULAR SECTIONS 04 Editorial / Guest Editorial 26 Book Review 06 News, Views & Analysis

27 Products

24 Tenders

29 Marketplace

24 Event List

30 List of Products & Advertisers

CHINA 1001 Tower 3, Donghai Plaza, 1486 Nanjing Road, West, Shanghai 200040, China Tel: +86-21 6289 – 5533 Ext. 368, Fax: +86-21 6247 – 4855 (Craig Shibinsky) Email: craig@ringier.com.hk Ringier Trade Media Ltd HONG KONG 9/F, Cheong Sun Tower, 118 Wing Lok Street, Sheung Wan, Hong Kong Tel: +852 2369 – 8788 Ext. 21, Fax: +852 2869 – 5919 (Octavia Au-Yeung) Email: octavia@ringier.com.hk Ringier Trade Media Ltd TAIWAN Room 3, Fl. 12, No. 303, Chung Ming S. Rd., Taichung, Taiwan Tel: +886-4 2329 – 7318 Ext. 16, Fax: +886-4 2310 – 7167 (Sydney La) Email: sydneylai@ringier.com.hk Ringier Trade Media Ltd GERMANY, AUSTRIA, SWITZERLAND Tel: +41-44 734 0472, Fax: +41 44 734 0680 Email: info@islerannoncen.ch USA Tel: (513) 527-8800 Fax: (513) 527-8801 Email: dhight@gardnerweb.com

Highlights of Next Edition Special Focus: HR in Pharma Note: ` stands for Indian rupee, $ stands for US dollar and £ stands for UK pound, unless mentioned otherwise

Looking For A Specific Product? Searching and sourcing products were never so easy. Just type MPH (space) Product Name and send it to 51818

eg, MPH Laboratory software and send it to 51818

USA Alfredo Domador, 6505 Blue Lagoon Drive, Suite 430 Miami, FL. 33126, USA Tel: (305) 448-6875, Fax: (305) 448-9942

GROUP CEO, NETWORK 18 B Sai Kumar CEO-PUBLISHING, INFOMEDIA 18 Sandeep Khosla EVP-HUMAN RESOURCES Sanjeev Kumar Singh ASSOCIATE VICE PRESIDENT Sudhanva Jategaonkar ADVERTISING SALES Shashin Bhagat (Ahmedabad) shashin.bhagat@infomedia18.in Mahadev B (Bengaluru) mahadev.b@infomedia18.in Hari Hara Subramaniam (Chennai) hari.s@infomedia18.in Prakash N (Coimbatore) prakash.n@infomedia18.in Kalyan Chakravarthy (Hyderabad) kalyan.chakravarthy@infomedia18.in Ameya Gokhale (Indore) ameya.gokhale@infomedia18.in Aayush Bidawat (Jaipur) aayush.bidawat@infomedia18.in Abhik Ghosal (Kolkata) abhik.ghosal@infomedia18.in Inder Dhingra (Ludhiana) inder.dhingra@infomedia18.in Surendra Kumar Agrawal (New Delhi) surendra.a@infomedia18.in Rohit Dass (Pune) rohit.dass@infomedia18.in Chirag Pathak (Vadodara) chirag.pathak@infomedia18.in MARKETING TEAM Ganesh Mahale, Prachi Mutha

NEWSSTAND AND SUBSCRIPTIONS DISTRIBUTION HEAD Sunil Nair DEPUTY GENERAL MANAGER Manoj Palsay SENIOR MANAGER - SUBSCRIPTIONS Sheetal Kotawdekar CO-ORDINATORS Rahul Mankar, Anant Shirke, Sarita Quadros, Chaitali Parkar, Kamlesh Mathkar, Vaibhav Ghavale

SERVICES SUBSCRIPTION SERVICES For subscription queries, write to chaitali.parkar@infomedia18.in or call +91 22 30034631-34 or toll free 1800 200 1021 PERMISSIONS For subscription to copy or reuse material from Modern Pharma, Write to spedit@infomedia18.in • Fortnightly Issue Price: ` 100 • Annual Subscription: ` 1200

Views and opinions expressed in this magazine are not necessarily those of Infomedia 18 Ltd, its publisher and/or editors. We at Infomedia 18 Ltd do our best to verify the information published but do not take any responsibility for the absolute accuracy of the information. Infomedia 18 Ltd does not accept the responsibility for any investment or other decision taken by readers on the basis of information provided herein. Infomedia 18 Ltd does not take responsibility for returning unsolicited material sent without due postal stamps for return postage. No part of this magazine can be reproduced without the prior written permission of the publisher. Infomedia 18 Ltd reserves the right to use the information published herein in any manner whatsoever.

Infomedia 18 Ltd is the publishing arm of Network 18.

Printed by Mohan Gajria and published by Lakshmi Narasimhan on behalf of Infomedia 18 Ltd. Senior Editor: Manas R Bastia Printed at Infomedia 18 Ltd, Plot no.3, Sector 7, off Sion-Panvel Road, Nerul, Navi Mumbai 400 706, and published at Infomedia 18 Ltd, ‘A’ Wing, Ruby House, J K Sawant Marg, Dadar (W), Mumbai - 400 028. Modern Pharma is registered with the Registrar of Newspapers of India under No. MAHENG / 2008 / 27125. Infomedia 18 Ltd does not take any responsibility for loss or damage incurred or suffered by any subscriber of this magazine as a result of his/her accepting any invitation/ offer published in this edition.


Modern Pharma•1-15 July 2012

6

News, Views & Analysis

DuBiotech to sign MoU with IDMA DUBIOTECH (Dubai Biotechnology and Research Park), the major life sciences cluster in the Middle East region dedicated to the biotechnology, pharmaceutical and medical devices, and healthcare technology industries, is planning to enter into an MoU with the Indian Drug Manufacturers’ Association (IDMA). This MoU will bring to the Indian lifesciences community, the business opportunities that the Middle East market can offer through the platform of DuBiotech Free Zone. DuBiotech will also be organising a Life Sciences Ambassador Networking Event in Mumbai for the Indian pharma industry and act as a gateway to the Middle East and UAE market in particular. This MoU will encourage the establishment of joint ventures between companies within DuBiotech and IDMA members, especially focussing on SMEs that account for 87 per cent of India’s total pharmaceuticals by volume, which comprises a major part of the total global production. DuBiotech can act as the ideal platform for SMEs to get the necessary global exposure to increase business prospects

manifold thus enabling them to become tomorrow’s MNCs. The companies operating from DuBiotech enjoy business benefits including 100 per cent foreign ownership, 100 per cent repatriation of profits, 100 per cent tax free operations, single window for government services, longterm lease, special customs exemptions and fast-track visa services. Indian businesses who have presence in DuBiotech are Wockhardt, Lupin, MSD Sun and NeoBiocon - a joint venture company between UAE-based Doshi Neopharma and the Indian biotech innovator Biocon. According to Manish Doshi, President, IDMA, “As India has a strong pharma-manufacturing industry, IDMA through the MoU with DuBiotech hopes to see symbiotic collaborations between Indian companies and Middle Eastbased academic and clinical expertise.

As Indian companies move towards extending their abilities to develop new products, DuBiotech can assist Indian companies to easily access regional networks to connect with institutions and companies with whom they can collaborate for shared benefits.“ Marwan Abdulaziz, Executive Director, DuBiotech & Enpark, TECOM Investments’ Science Cluster, said, “We have perceived a high interest among the life sciences companies in India towards DuBiotec Through our cost-effective and enabling services we hope that Abdulaziz several biotech companies from India will invest in DuBiotech, which will not only prove a great addition to our portfolio, but will also support the UAE’s vision of strengthening the economic synergy between the two countries.” DuBiotech accommodates the entire life sciences value chain by providing

DHL opens lifesciences and healthcare distribution centre in Mumbai DHL Supply Chain, the global market leader for contract logistics solutions has opened a new distribution centre for the life sciences and healthcare industry in Mumbai. This first state-of-theart life sciences facility is located within a newly constructed 56,000 square metre multi-customer distribution centre and will cater to the requirements of the rapidly growing life sciences industry in one of the most important emerging life sciences & healthcare markets in the world. “The new platform in Mumbai will enable us to provide a world-class service to

Anand

our customers, enabling them to expand their businesses. We have the capabilities to distribute to wholesalers, pharmacists and hospitals from our new centre in Mumbai based on customer demands,” said Vikas Anand,

Bharat Biotech receives $ 4 million from the Wellcome Trust BHARAT Biotech and The University of Maryland Center for Vaccine Development (CVD) received a $ 4-million Strategic Translation Award from The Wellcome Trust for clinical development of a new conjugate vaccine including initial clinical trials beginning in three years to prevent the potentially lethal infectious disease caused by invasive NonTyphoidal Salmonella (NTS). NTS has emerged as an important cause of invasive bloodstream infection Dr Ella in Sub-Saharan Africa, among young children with malaria and malnutrition, and among adults with HIV. Strains of NTS that can cause systemic disease such as meningitis or sepsis are particularly common in sub-Saharan Africa; approximately

20 to 30 per cent of children with such invasive NTS infections die. “The impact, importance of academic and industry partnership is far reaching. The CVD NTS project is a testimony of our belief in collaborative research and our commitment to introduce highly effective and affordable vaccines to solve regionspecific neglected diseases in the developing world,” said Dr Krishna Ella, CMD, Bharat Biotech. Adding to this Professor Myron Levine, Director, CVD, said, “It is an imprimatur, because of the prestige associated with the Trust’s involvement, the rigorous vetting process, and the opportunity for the University, in collaboration with Bharat Biotech, to bring forth a potentially life-saving vaccine for an underserved population.”

COO, DHL Supply Chain India. He added, “For Mumbai multiclient site we have built strong managerial and operational personnel teams. In addition to warehousing expertise, we have also hired staff with temperature controlled logistics expertise; the purpose is to manage day-to-day operations as per DHL’s global standards. We are in the process of launching more multi-client sites across key cities in India. The new centres will be set up at Gurgaon, Bengaluru, Chennai, Ahmedabad, Central India, Kolkata and North India.” -Chandreyee Bhaumik

Device to produce 3-D focussing of stream of cells TONY Jun Huang and his colleagues at Penn State have designed a device that can focus particles or cells in a single stream and perform 3-D optical assessments for each cell. This device is believed to represent a low-cost flow cytometry chip used for clinical diagnosis in hospitals, clinics and field. Huang said, “HIV is diagnosed based on counting CD4 cells. Ninety per cent of the diagnoses are done using flow cytometry.” According to researchers, inexpensive, portable devices that can rapidly screen cells for leukaemia or HIV may soon be possible, thanks to a chip that can produce threedimensional focussing of a stream of cells.

key facilities, investing in infrastructure and creating a unique free zone with ready transport and business links to the whole of the Middle East, Asia, Europe and the USA. In fact, the UAE itself is considered to be the second-largest consumer of pharmaceutical products in the Gulf after Saudi Arabia with the market valued at around $ 640 million. The pharmaceutical industry in the UAE also benefits from re-export markets such as Iran, Pakistan, Yemen and Somalia, which are major buyers of re-exported pharmaceuticals from the country. DuBiotech, in tie up with the US-based Research Triangle Institute International (RTI), has developed COPs based on international best practices covering all activities related to clinical research & clinical trials, manufacturing & environment, and health & safety. The Park is also working closely with the UAE Ministry of Health, the Dubai Health Authority, to maintain quality of development within the life sciences industry. This is evident from the fact that the UAE is second in the region in terms of capital invested in the pharma sector.

Azad stresses on importance of US FDA collaboration GHULAM Nabi Azad, Union Minister for Health and Family Welfare, Government of India, recently visited the headquarters of the US FDA at Maryland. He stressed on the importance of collaboration with the USA in food and drug regulation as this would provide exposure to the Indian regulators to international best practices in this area. Azad highlighted the importance of drug and food regulation in the lives of common people. He said that the Indian pharma industry, estimated to be worth about $ 20 billion, is ranked third globally in terms of its volume and 13th in terms of its worth. The Union Minister noted that India is regarded as the ‘Pharmacy of the developing world’ due to the focus on accessibility and affordability. Azad also spoke on the drug and food regulatory framework in India. He explained the roles of the Union and State governments in the regulatory framework of food safety, as it is a concurrent subject within the Constitution of India.

OTC market grows 4.5 per cent NICHOLAS Hall & Company’s DB6 2012 recently stated a $ 110 billion OTC market. The global OTC market grew by 4.5 per cent in 2011 up from 3.8 per cent in 2010. The emerging markets showed more growth over developed markets. Brazil is the key for emerging markets in Latin America. Asia-Pacific grew by 5 per cent - while east and south east Asia recorded 7.7 per cent growth, the Indian sub-continent recorded robust growth of almost 11per cent. Despite a double digit decline, suspension of manufacturing and recalls in the US, J&J still holds the position as the world’s number one OTC maker. Novartis i in the second place with a small margin ahead of Bayers in the third place and GSK dropping to fourth place. Sanofi at the fifth position has showed the highest growth. With the acquisition of Nycomed, Takeda made an entry to the top 10 list. The top 10 companies form 27.2 per cent market share in 2011, down from 29.7 per cent five years ago. Genomma is the best performer in the Top 100, with a five year CAGR of 26.3 per cent. Nicholas Hall said, “The reason MNCs cannot grow is because they underperform in the emerging markets, and because of low growth in North America and West Europe where they are strong.”


Modern Pharma•1-15 July 2012

News, Views & Analysis

AMRI hires two new experts for its Hyderabad Centre AMRI, a leading global contract research and manufacturing organisation, has expanded its discovery capabilities in India by hiring two experts in medicinal and computational chemistry at its research centre located in H y d e r a b a d . Dr Nanduri The company also announced the completion of the relocation of custom library synthesis resources and capabilities to Hyderabad Research Centre from its Budapest, Hungary operations. Subramanyam Maddala, President of India Operations said, “Dr Srinivas Nanduri, Director -Medicinal Chemistry, India and Dr Suneel Kumar, Bommisetty, Senior Research Associate –Computational Chemistry bring a high level of medicinal chemistry expertise, a strong track record of industry experience and additional drug discovery project management experience to the Hyderabad site.” He added, “AMRI is committed to providing best-of-class services

Sanofi announces results of ORIGIN SANOFI recently announced results from the landmark Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial, which showed that Lantus® (insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period. Results also showed that insulin glargine delayed progression from pre-diabetes to Type 2 diabetes and there was no association between insulin glargine use and increased risk of any cancer. ORIGIN was a six-year randomised

clinical trial designed to assess the effects of treatment with insulin glargine versus standard care on CV outcomes. “We now know more about insulin glargine than about any other glucose lowering drug with respect to future health outcomes,” commented Dr Hertzel Gerstein, McMaster University, Hamilton, Ontario/Canada and Principal Investigator, ORIGIN trial. “Specifically, it maintains excellent glycemic control, slows progression of dysglycemia and has no long-term serious health effects. Moreover, this academically led and analysed trial is an excellent example of collaboration between industry and academia.” Dr Ramachandran, President, India Diabetes Research Foundation and National Co-ordinator, ORIGIN trial for India, shared, “I am very happy to have participated in this landmark study not only as the National Coordinator from India, but also as the co-author of the ORIGIN primary papers published in New England Journal of Medicine (NEJM).”

to our customers, and servicing the entire value chain of contract research services. These additions enhance our capabilities to move towards that target.” Bruce J Sargent, Senior VP - Drug Discovery, commented, “At AMRI we continue to expand our Dr Bommisetty world-class team of scientists to ensure our customers have access to the most experienced and technically adept experts to address their increasingly complex challenges. With the addition of Dr Nanduri and Dr Bommisetty, AMRI expands its global medicinal and computational chemistry capabilities in India, complementing the existing capabilities in the US and Singapore.” He added, “Strengthening our HRC capabilities is an essential element of our SMARTSOURCING™ strategy, which brings together the right mix of AMRI global services, capabilities and translational expertise, while maintaining the same high standards for performance, quality and productivity.”

Industry in pact with academic researchers SEVEN pharmaceutical companies and four research institutions, working with the Bill and Melinda Gates Foundation, have launched a partnership to expedite the discovery of new treatments for Tuberculosis (TB). The partnership, ie TB Drug Accelerator (TBDA), will target the discovery of new drugs by collaborating on early-stage research. Existing drugs, all at least 50 years old, require six months to cure the disease – a lengthy process that contributes to 20-30 per cent of patients dropping out before completion. Aided by nearly $ 20 million from the Gates Foundation, the partners launched the TBDA in April and have begun the first round of screening for new candidates. The TBDA aims to develop five pre-clinical drug candidates with treatmentshortening potential within 5 years and proof-of-concept for a

one-month three-drug regimen within 10 years. “The TBDA establishes a new paradigm of co-operation in drug discovery,” said Chris Viehbacher, CEO, Sanofi. He added, “By working together on this, we can optimise our research and add speed to the development of one of the most pressing needs in global health.” Through this partnership, the participating pharmaceutical companies Abbott, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck and Sanofi – will open up targeted sections of their compound libraries and share data with each other and four research institutions: the Infectious Disease Research Institute; the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health; Texas A&M University; and Weill Cornell Medical College.

7


Modern Pharma•1-15 July 2012

8

News, Views & Analysis

Boehringer, Lilly in pact THE Boehringer Ingelheim – Lilly alliance in India now offers oral anti-diabetics as well as contemporary injectable insulins. Boehringer Ingelheim – Lilly announced the launch and commercial availability Tyagi of Linagliptin (TrajentaTM) 5 mg filmcoated tablets, their original research product in India. It is also approved in the US, the EU and Japan along with India. The approval of the drug was based on a clinical trial programme, which involved approximately 6,000 adults with Type 2 diabetes.

Spuy

Sharad Tyagi, Managing Director, Boehringer Ingelheim, India, said, “This alliance combines the strengths of two of the world’s leading pharma companies. While the combined field force provides the spread to touch doctors treating diabetes across the

country, the new launch provides more choice to the clinician.” Commenting on the launch, Melt van der Spuy, Managing Director, Lilly, India, said, “This launch of Linagliptin (TrajentaTM) marks an important milestone for the alliance, demonstrating our ongoing commitment to providing pioneering healthcare solutions.” He added, “The alliance will continue to focus on bringing to India innovative products and services to address the unmet patient needs amid the growing Indian diabetes epidemic.”

Wockhardt honoured with 2012 DIANA award WOCKHARDT’S US subsidiary, Wockhardt USA Inc was recently honoured with the presentation of the 2012 DIANA Award by the Healthcare Distribution Management Association (HDMA) for the ‘Best Overall Generic Product Manufacturer’ with sales of up to $ 100 million in the healthcare distributor market at their prestigious annual business & leadership conference in Dr Khorakiwala San Antonio, Texas. “This award from HDMA is particularly significant and encouraging to Wockhardt’s efforts in building strong relationships with our distributors and partners,” said Dr Habil Khorakiwala, Founder Chairman & Group CEO, Wockhardt. He further informed, “We are indeed honoured and elated with this recognition from HDMA.”

Thermolab’s stability chamber awarded STABILITY Chamber, one of the core products of Thermolab Group, was awarded with India Design Mark, a global design quality mark for a product, by Ministry of Commerce & Industry, Government of India. India Design Mark, popularly known as I-Mark, is granted by India Design Council, an autonomous body established by the Government of India in collaboration with Japan Institute of Design Promotion.

“It is a great honour that our product has been awarded with a global quality mark. It is a pleasure to receive such recognition from the Government of India through India Design Council. It is an assurance of quality product and that is what matters the most to any customer and in any business. He would

Mhatre

prefer to choose a product that has guaranteed quality while making a choice,” said Sandip Mhatre, MD, Thermolab Group. I-Mark symbolises excellence in product in terms of form, function, quality, safety, sustainability, innovation and communicates that

the product is usable, aesthetically appealing and socially responsible. It was granted after following a careful evaluation process aimed at identifying good design that exceeds the prescribed criteria of evaluation. This is the second award for Thermolab besides the India Leadership Award for industrial development received last year.

Kenta’s KBSA301 under phase I/II of clinical trial

Pharma wholesale and distribution market to reach $ 747 billion by 2014

KENTA Biotech recently announced the enrollment of its first set of patients to test KBSA301 in the phase I/ II clinical trial. KBSA301 is a fully human monoclonal antibody that binds to staphylococcal alpha-toxin released by both MRSA and MSSA strains, thus preventing the toxin from damaging the lungs of the patients suffering from pneumonia. This is one of the few therapeutic monoclonal antibodies that is tested in a first-in-human trial directly in patients. Kenta Biotech obtained permission from health authorities in four major countries to test the antibody on intensive care unit patients with severe S. aureus pneumonia. Franco Merckling, CEO, Kenta Biotech, said, “This is a great day for patients,

ACCORDING to a new report by Visiongain, the world market for pharmaceutical Wholesale and Distribution (W&D) activities will reach $ 747 billion for 2014. The pharma industry and its supply chain partners will increase revenues from 2012 to 2022. New products – novel small molecules, generics and biologics – will stimulate the pharma W&D market. Many opportunities for rising drug sales exist, with high, growing W&D revenues possible from 2012 to 2022. There will be increasing dependence on emerging countries, with their fast-rising drug sales. Developed countries hold promise too, the study notes.

for doctors and for Kenta Biotech. Thanks to intensive research and the dedication of our outstanding staff, we are able to bring a human monoclonal antibody with an innovative mode of action into clinical development in record time. I am confident that this trial will deliver promising data and pave the way for change in the treatment of severe S. aureus pneumonia.” Toni Perez, Chief Medical Officer, Kenta Biotech, said, “We are very excited about this clinical trial. For more than 25 years, I have been developing new anti-infective drugs, and I have never seen a drug with such tremendous potential. Patients and doctors have been eagerly waiting for a solution like the one to be expected from KBSA301.”

Kritika Chaudhari, Industry Analyst - Pharmaceuticals Visiongain, explained, “Growth in the global pharmaceutical wholesale and distribution market to 2022 will be driven by the ageing world population and increasing demand for medicines of all types.” Visiongain’s report provides revenue forecasts to 2022 at world market, submarket, company and national level. It

forecasts world sales for the main submarkets of, original-branded drugs and generic drugs. Research, data and analyses cover activities of McKesson, Cardinal Health, AmerisourceBergen, Phonix Group and other companies, with revenue forecasts. The scope of the field widens, with organisations collaborating and expanding their businesses. The study also discusses business activities and commercial news, shows research interviews with external authorities and forecasts revenues in leading national markets. The work analyses the US, Japan, EU5 countries, Brazil, Russia, China and India.

Modi Omega Pharma organises CME on efficacy of natural sea water MODI Omega Pharma recently organised a Continued Medical Education (CME) programme on the efficacy of natural sea water in post nasal surgeries. The CME was conducted at India Habitat Centre, New Delhi in association with South Delhi ENT club. The event witnessed

the coming together of nearly 25 eminent ENT specialists from reputed hospitals of the city. Dr Girish Raheja, ENT Surgeon, Indraprastha Apollo Hospital, New Delhi, highlighted how natural sea water yields better results than saline water in post nasal

surgeries. He emphasised upon the various advantages of natural sea water such as reducing nasal congestion without harming nasal lining, removing excess mucus, preventing the risk of infections such as otitis and outbreaks of common colds, etc.

Himani Modi, Director, Modi Omega Pharma, commented, “The company holds such symposiums on a regular basis as these events provide the doctors with a platform to be updated about the latest developments that take place in the medical

fraternity. It has always been our endeavour to update and disseminate scientific information through these CMEs. This CME particularly would throw light on the new techniques and modes of treatment that can be adapted for nasal surgeries.”


Modern Pharma•1-15 July 2012

News, Views & Analysis

Makov, new Chairman of Sun Pharma THE Board of Directors of Sun Pharmaceutical Industries Ltd have announced the appointment of Israel Makov as Chairman of the Board. Makov is the former President and CEO of Teva Pharmaceutical Industries Ltd (2002-2007). He is among Israel’s most respected corporate leaders, and is widely credited with Teva’s emergence Makov as a global company and a world leader in generic pharmaceuticals. Speaking on the induction, Dilip Shanghvi, Managing Director, Sun Pharma, said, “I welcome Makov on behalf of the entire Board and the

larger Sun Pharma team. He is an exceptional leader with deep knowledge and experience in globalising businesses successfully. As Sun Pharma continues to rapidly expand its presence worldwide, I am sure that we will benefit immensely from his experience.” On his appointment, Makov said, “Sun Pharma is an exciting company poised for substantial global expansion and I look forward to working together with Dilip and his team in realising their visionary goals.”

9

Imaging portfolio of Piramal shows potential to detect Alzhiemer’s PIRAMAL Imaging SA, a subsidiary of Piramal Healthcare Ltd, presented data on several compounds from its molecular imaging portfolio at the Society of Nuclear Medicine’s 59th annual meeting in Miami Beach, Florida, from June 9 – 13. Data from five florbetaben studies were featured, including results from a pivotal phase III trial, which would provide the basis for regulatory submission later this year. Florbetaben, a latestage amyloid imaging agent being studied as a potential tool to aid in the diagnosis and assessment of Alzheimer’s disease, is the lead compound in the portfolio. Historically, the only way to definitively diagnose Alzheimer’s disease has been

Dr Piramal

after death – at autopsy – through analysis and identification of beta-amyloid in brain tissue. “What better way to introduce Piramal Imaging to the nuclear

medicine community,” said Dr Ludger M Dinkelborg, CEO, Piramal Imaging. “We believe we have the richest molecular imaging portfolio in the industry today, and the range of research we are presenting here reflects the depth, diversity and clinical relevance of our pipeline.” Piramal Imaging is developing an innovative and proprietary tracer portfolio to address major clinical needs in Alzheimer’s disease, prostate cancer, lung cancer, liver cancer and cardiovascular disease. “Our goal is to be a leader in molecular imaging through increased diagnostic accuracy of serious medical conditions to improve patient care,” said Dr Swati A Piramal, Director, Piramal Healthcare Ltd.

CCI issues order against CDA, Goa THE Competition Commission of India (CCI) has found Chemist & Druggist Association, Goa (CDAG) in violation of the provisions of the Competition Act, 2002 which deals with anticompetitive agreements. The Commission has imposed penalty of ` 2 lakh @ 10 per cent on the average of the receipts for financial year 2008-09, and 2009-10 on CDAG. CCI has termed the imposition of guidelines by CDAG that lay down the margins for wholesalers and retailers as anti-competitive and against the interests of the consumers. As part of these guidelines, the CDAG had prescribed a cap on the amount of the discount a wholesaler can give to the retailer and prohibited the retailer from giving any discounts to the consumers. CCI has directed CDAG to remove the clauses in the circulars, MoU and guidelines and file an undertaking to this effect within 60 days from

the date of receipt of the order. The case was initiated on a complaint filed by Varca Druggist & Chemist through its proprietor and proprietors of two other pharmaceutical drugs and medicines firms before Director General, Monopolies and Restrictive Trade Practices Commission (MRTPC). The case was later transferred to the CCI and investigation was conducted by Director General, CCI. The Commission has held that in such a situation, when efforts are being made to ensure supply of drugs to the common man at a cheaper rate, the restrictive guidelines of Chemists and Druggist Association work as stumbling block. Such guidelines of CDAG do not appear to be in line with the government plans to provide medicines to common man at an affordable rate. In view of the aforesaid, the Commission was of the view that CDAG not only limits and

controls supply of drugs in the market through a system of seeking mandatory PIS approvals and limit and control the number of players by insisting on obtaining its No Objection Certificate (NOC) for appointment of stockist but also through its guidelines fixes trade margins for the wholesalers and retailers which, in turn, results in determination of sale price of drugs in the market. Therefore, the Commission has held that CDAG had violated the provisions of Section 3(3)(a) and 3(3)(b) of the Act.

Takeda completes URL acquisition TAKEDA Pharmaceutical Company Ltd (Takeda) and its wholly owned subsidiary, Takeda Pharmaceuticals US (TPUSA), jointly announced that Takeda’s wholly owned subsidiary, Takeda America Holdings, Inc, has completed its acquisition of URL Pharma, Inc for an upfront payment

of $ 800 million. The deal also includes an agreement for future performance-based contingent earn out payments. With the completion of the acquisition, TPUSA will begin the integration of URL Pharma and will immediately assume responsibility for the marketing and promotion

of Colcrys (colchicine), URL Pharma’s leading product and an important therapy for the treatment and prevention of flares associated with gout. The acquisition will result in an immediate increase in revenue with estimated FY 2012 net sales of more than $ 550 million.

Fraunhofer sets up research centre in Glasgow EUROPE’S largest contract research organisation Fraunhofer will be setting up a research centre for Applied Photonics at UK at the University of Strathclyde in Glasgow. The centre will be a hub for industry-driven laser research and technology for a variety of sectors including healthcare, security, energy and transport. The new Fraunhofer Centre is funded by Fraunhofer and the University, the Scottish Government, Scottish Enterprise and the Scottish Funding Council. Michael Russell,

Education Secretary, said, “Glasgow has a global reputation for advanced research and technology. Securing the UK’s first Fraunhofer centre is a major achievement for the University of Strathclyde’s Technology and Innovation Centre.” Professor Jim McDonald, Principal, University of Strathclyde, said, “By working sideby-side with colleagues in business, industry and government, we are finding solutions to global challenges, enhancing industry innovation and competitiveness and supporting the economy.”

The CDAG and its members had been directed to cease and desist from indulging in and following the anticompetitive practices. The order further directs CDAG to file an undertaking that guidelines and MoU with respect to non-appointment of a stockist or a wholesaler from among the non-members of the CDAG, requirement of NOC from the CDAG for appointment of stockist or wholesaler and limit on the number of stockist of pharma companies as well as the clauses mandating compulsory PIS approval from CDAG for introduction of drugs in the territory of Goa and requiring routing of bids for supply of drugs to the government and the hospitals through authorised stockist only have been done away within 60 days from the date of receipt of the order.

Mini valves to maintain low flow rates MAINTAINING flow rates is very important in analytical chemistry and clinical diagnostic practices. Bio-Chem Fluidic designed a new range of 038T Isolation Mini-Valves that provides a completely inert, non-metallic path Mini valves for highly aggressive and high purity fluids. The valves high efficiency solenoid that are designed for extremely low consumes only two watts at flow rates. Bio-Chem Fluidics 12 or 24 VDC for minimal is a world leading manufacturer heat generation. of inert, miniature fluid Fluid contact is restricted handling components. to the valve body and the The new range of Mini- flexible diaphragm. Valves Valves includes the 038T2B are constructed from (bottom-ported) and 038T2S highly inert polymers and (side-ported) normally-closed non-contact parts. The valves valves with ¼- 28 UNF offer bi-directional flow and threaded ports. 038T Mini- are also available in a manifold Valves has a custom designed mount configuration.


Modern Pharma•1-15 July 2012

10

News, Views & Analysis

In Brief Sandoz recalls Introvale birth control pills over packaging error SANDOZ is recalling 10 lots of its generic Introvale birth control pills because of a packaging error. The Introvale product contains 84 active pills that are peach coloured and seven inactive pills that are taken in the 13th week are white. Sandoz stated that it decided on the recall after a consumer reported that white inactive tablets were mistakenly placed in the wrong row labelled week nine.

Upsher-Smith to pay $ 555 million for Proximagen US drugmaker, Upsher-Smith Laboratories, is set to buy British Group Proximagen for £ 223 million ($ 347 million) plus further payments potentially worth up to £ 134 million based on the success of two experimental drugs. Proximagen has drugs in early-stage development for central nervous system disorders, cancer and inflammation. It also has a treatment for obesity known as PRX00933.

Jazz Pharmaceuticals completes EUSA Pharma acquisition JAZZ Pharmaceuticals announced the closing of its acquisition of EUSA Pharma, a privately-held, speciality pharmaceutical company with a commercial presence in the US and EU and a global distribution network. Following the closing, Jazz Pharmaceuticals now also markets a portfolio of oncology and critical care products outside the US, including Erwinase®, leveraging EUSA Pharma’s international sales and marketing capabilities.

Lupin sales and operating profit up 22 per cent LUPIN Ltd recently reported its performance for the fourth quarter and financial year ended, March 31, 2012. Gross sales grew by 22 per cent to ` 70,017 million during FY12, up from ` 57,422 million and net sales grew by 22 per cent to ` 69,597 million during FY12, up from ` 57,068 million (FY11). Further, Earnings before Interest, Tax, Depreciation and Amortisation (EBITDA) grew by 22 per cent to ` 14,590 million during FY12, up from ` 12,000 million (FY11). Dr Kamal K Sharma, MD, Lupin Ltd, said, “We have had another strong year where the company has clocked in a growth of 22 per cent in revenues as well as operating profits. We are in the midst of a very exciting period for Lupin with multiple launches, significant ramp-up in business and judicious investments planned.”

Ubichem boosts fine chemical output with Hungary plant UBICHEM has expanded its pharmaceutical ingredient capabilities through the opening of a 590,000 sq ft plant in Hungary. The facility will produce industrial quantities of starting materials, intermediates and other fine chemical products for pharmaceutical and other applications. Having added the facility, Ubichem now offers services spanning from process research and development to commercial-scale production.

PAREXEL introduces the MyTrials™ platform PAREXEL International Corporation, a leading global biopharmaceutical services provider, recently announced the launch of the MyTrials™ platform, a fullyintegrated e-clinical solution that simplifies the clinical trial process. Developed by PAREXEL’s technology subsidiary Perceptive Informatics, PAREXEL MyTrials is an e-clinical platform designed by clinical research experts to provide comprehensive support for the drug development process.

J&J completes Synthes acquisition JOHNSON & Johnson (J&J) completed the acquisition of Synthes, Inc for a purchase price of $ 19.7 billion in cash and stock. Synthes will now be integrated with DePuy franchise to establish DePuy Synthes Companies of J&J. “The acquisition creates the world’s most innovative and comprehensive orthopaedics business and reflects our long-standing strategy of leadership within attractive healthcare markets,” said Alex Gorsky, CEO, Johnson & Johnson.

Sanofi and Joslin in pact for diabetes research SANOFI and the Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School, recently announced a new collaboration to promote the development of new medicines for the treatment Zerhouni of diabetes and related disorders. Joslin Diabetes Center is the world’s leading diabetes research and clinical care organisation. The collaboration was unveiled at the 2012 Bio International Convention in Boston, MA. Building on Joslin’s experience in diabetes research and care, the collaboration will focus on four key areas within diabetes and related metabolic disorders to identify potential new biologics or small drug candidates for the treatment of late complications of diabetes and new insulin analogs with more targeted efficacy. Additionally, research will address the challenges of insulin resistance and personalised medicine, with the overall aim of improving the lives of people living with diabetes. Dr Elias Zerhouni, President, Global R&D, Sanofi, commented, “This collaboration brings together two important forces in diabetes therapy – Sanofi Diabetes and Joslin Diabetes Center, which have the potential to define new pathways towards better understanding

the nature of this disease and developing new treatments. This collaboration further demonstrates Sanofi’s commitment to improving diabetes management and care through the development of innovative research strategies.” Under the terms of the agreement, Sanofi has options to commercialise the results of the research. Both parties will have access to intellectual property for internal research use. Adding to this, C Ronald Kahn, MD, Mary K Iacocca, Professor of Medicine, Harvard Medical School and Chief Academic Officer, Joslin Diabetes Center, who will head the alliance team said, “This opportunity brings together experts from the pharmaceutical industry with our team of scientists and clinicians, who are The research devoted to research and clinical care for will address the diabetes and related challenges of metabolic disorders. insulin resistance The result should and personalised be a very exciting medicine, with the collaboration with aim of improving the great potential for lives of diabetics. innovative research that will participate to advance diabetes treatment and patient care.” As a company Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalised solutions. To meet the set targets Sanofi initiated the collaboration, with the motive to bring forth a change.

A drug that destroys cancer stem cells A drug thioridazine, discovered by scientists at McMaster University in Ontario, Canada proves to kill cancer stem cells with little effect on the healthy cells. “The unusual aspect of our finding is the way this humanready drug actually kills cancer stem cells; by changing them into cells that are noncancerous,” said Mick Bhatia, Principal Investigator for the study and Scientific Director, McMaster’s Stem Cell and Cancer Research Institute. The university researchers have also pioneered a fully automated robotic system to test and identify drugs. “Now we can test thousands of compounds, eventually defining a

Bhatia

candidate drug that has little effect on normal stem cells but kills the cells that start the tumour,” said Bhatia. Cancer stem cells have said to be the root for causing cancer. The drug aims at targetting the root and thus preventing the reoccurrence

of cancer. Specially designed clinical trials will be done on patients with the history of relapse of acute myeloid leukaemia after treatment with chemotherapy. Bhatia’s team found thioridazine works through the dopamine receptor on the surface of the cancer cells in both leukaemia and breast cancer patients. They have suggested that it can be used as a biomarker that would allow early detection and treatment of breast cancer and early signs of leukaemia. In addition, the team will explore several drugs identified along with thioridazine and also the effect of the drug in other types of cancer.

Valeant to buy OraPharma for $ 312 million VALEANT Pharmaceuticals International Inc, Canadian specialty pharma company, recently declared that it would buy privately held OraPharma from private equity firm Water Street Healthcare Partners for about $ 312 million. This step will help it make an entry into the dental market. Further, Ontariobased Valeant that has recently embarked on an aggressive acquisition spree, will also pay up to $ 114 million in potential contingent payments based on

OraPharma currently has the largest specialised pharma sales force in the dental industry, and as of March 31, had revenue of approximately $ 95 million.

certain milestones, including revenue targets. OraPharma currently has the largest specialised pharma sales force in the dental industry, and as of March 31, had revenue of approximately $95 million. Michael Pearson, Chairman and CEO, Valeant Pharmaceuticals, said, “We are excited to enter a new attractive market segment with an already established sales infrastructure focussed entirely on the dental community.”


Modern Pharma•1-15 July 2012

News, Views & Analysis

Waters India celebrates silver jubilee

In Brief Takeda Pharmaceutical to stop selling 13 Pfizer, Inc Drugs in Japan A report states that Takeda Pharmaceutical Co Ltd will stop distributing 13 Pfizer, Inc drugs it now sells in Japan at the end of this year and Pfizer itself will begin selling them from 2013. The 13 drugs include antibiotic minomycin, anticancer agents torisel and mylotarg, and depression treatment amoxan. The list did not include Viagra. Takeda will continue to distribute Prevenar, a pneumococcus vaccine for children, and the haemophilia B drug BeneFIX. It also said it and Pfizer will continue to work together on the arthritis drug Enbrel.

Ambrx collaborates with Merck

L-R: Venugopalan; Caputo; Rohit Khanna, VP - Worldwide Marketing and Mike Harrington, VP, European & Asia Pacific Operations

WATERS India Pvt Ltd, a fully owned subsidiary of Waters Corporation (USA), recently celebrated the silver jubilee anniversary of its successful operations in India on June 8, 2012 in Bengaluru. Driven by a long-term commitment to the region, Waters had the vision 25 years ago to invest in India as the first analytical science company to incorporate in the country by creating a joint venture with local partners in 1988. “What attracted us 25 years ago to India is the same thing that motivates us today; we continue to welcome the opportunity to work with and

contribute to one of the most exciting economies in world,” said Art Caputo, President, Waters Division, Waters Inc. He further said, “We have witnessed the impact science has made on India and its global leadership in pharma and life sciences as well as food production.” He continued, “Understanding scientific challenges through cooperation, Waters’ strategy is to invest in local service and support, and to focus on partnerships tailored to meet the needs of India’s leading organisations. We consistently invest in Waters

India to create the best infrastructure in India.” “India has always proven itself to have great potential in the field of pharmaceuticals. World over Waters generates 65-70 per cent of its business from pharmaceuticals, but it is only India that generates 90-95 per cent of our business from the pharmaceutical sector. Hence, we feel extremely lucky to have foreseen the potential India has and be one of the first analytical companies in India,” informed K V Venugopalan, President, Waters India Pvt Ltd. -Jasleen Kaur Batra

AMBRX has entered into a collaboration with Merck to design and develop rationally optimised biologic drug conjugates based on Ambrx’s site-specific protein medicinal chemistry technology. “Ambrx’s technology has the potential to provide the foundation for a new family of biologic drug conjugates that selectively deliver small molecules to their site of action. Merck’s deep disease area expertise made it the partner of choice in expanding the application of this technology beyond oncology to other important disease areas,” said Peter G Schultz, PhD, Scientific Founder and Board Member, Ambrx.

iBio announces important expansion of its intellectual property portfolio IBIO, Inc recently announced that the US Patent Office had allowed patent application 11/706, 576 entitled ‘Bacillus anthracis antigens, vaccine compositions, and related methods.’ The claims cover compositions and methods for fusions of sequences of Bacillus anthracis antigens for Protective Antigen (PA), Lethal Factor (LF) and Edema Factor (EF), and combinations thereof to LicKM, which is part of the company’s iBioModulator™ platform. The iBioModulator platform has been shown to be applicable to a range of vaccine proteins, and can significantly modify the immune response to a vaccine in two important ways.

11


Modern Pharma•1-15 July 2012

12

News, Views & Analysis

In Brief Leading pharma ingredients event makes successful ASEAN debut BM Live, announced that over 4,300 visitors attended the latest event to join its global UBM Pharma Portfolio, CPhI Southeast Asia (SEA) 2012, which ran from May 10-12, 2012 at the Jakarta International Expo in Indonesia. The event, which was the first-of-its-kind in the ASEAN region, featured 220 exhibiting companies from 24 countries. The international line-up was further supported by pavilion representation from CCCMHPIE (China Chamber of Commerce for Import & Export of Medicines & Health Products), Pharmexcil, CCPIT (CCPIT Sub-Council of Chemical Industry - China) and Korea.

USFDA approves GSK, Xenoport drug for new use GLAXOSMITHKLINE (GSK) and XenoPort have received approval from the US FDA to sell Horizant to treat post-herpetic neuralgia. The medicine is already approved as a treatment for restless legs syndrome. XenoPort will receive a milestone payment of $ 10 million from GSK following first sales of the drug in its new use.

Sal Pharma and Pan Drugs gets FDA warning letter for not registering drugs TWO Indian companies, Pan Drugs and privately-held Sal Pharma, have got warning Letters from American drug regulator for not fulfilling the mandatory registration requirements. The US FDA had earlier pointed out to both the Indian companies regarding their noncompliance to the US registration laws, but the companies did not take adequate corrective steps, FDA said.

India is the future market for nutraceuticals: Study

NEW analysis from Frost & Sullivan finds that the Indian nutraceutical market earned revenues of $ 1480 million in 2011 and could grow to $ 2731 million by 2016 at a CAGR of 13 per cent. Dietary supplements were the largest category accounting for 64 per cent of the nutraceuticals market, driven primarily by the pharmaceutical sector in the form of vitamin and mineral supplements. Functional food and beverages is still in the infant stage since India still looks up to traditional practices like Ayurveda. Functional foods will be the quickest growing category until 2015 followed by dietary supplements. However, dietary supplements, specifically herbal and dietetic supplements, will form cream areas for nutraceutical manufacturers, driven by growing demand from an evolving consumer base.

The global nutraceutical market in 2011 was estimated to be $ 149.5 billion, with US, Europe and Japan being the largest regional markets, accounting for nearly 93 per cent of the global nutraceutical demand. These markets are nearing maturity, with exceedingly high per capita spends on nutraceutical products (Japan has a per capita spend of $ 51/year, while US and Europe have $ 40 and $ 35 each. The global average is only $ 21/person/year). Thus, nutraceutical manufacturers look at developing countries with considerably lower per capita spends as key growth regions. Pharmaceutical and FMCG giants dominate the Indian nutraceutical market. While dietary supplements such as vitamin and mineral supplements have been captured by pharmaceutical companies, FMCG companies are now bringing functional food and beverages to the market. Certain segments like dietetic supplements are now being catered to by pure-play nutraceutical companies, apart from their pharmaceutical and FMCG counterparts. The study suggests that manufacturers need to focus on inclusion of natural health benefitting extracts for their products which allows them to have traditional brand identity that will also allow middle class consumers to connect with the brand on a cultural level.

Bausch + Lomb completes the acquisition of ISTA Pharmaceuticals BAUSCH + Lomb, the global eye health company, recently announced that it had completed its acquisition of ISTA Pharmaceuticals, Inc, a leading pharmaceutical company. The addition of ISTA bolsters Bausch + Lomb’s product portfolio and pipeline, increasing the company’s therapeutic offerings for physicians and their patients and creating opportunity for future growth. “Together, we are building a high-performance company that can deliver even more benefits for the patients and customers,” said Brent Saunders, President and CEO, Bausch + Lomb.

EMD Serono Inc strengthens leadership teams EMD Serono, Inc, a subsidiary of Merck KGaA, Darmstadt, Germany, has announced the appointments of Allene Diaz, Senior Vice President, Head - US Oncology; Evan Lippman, Senior Vice President - Neurodegenerative Diseases and Rheumatology; Rami Levin, Vice President - Marketing, Neurodegenerative Diseases and Rheumatology; and Craig Millian, Senior Vice President, Head - US Fertility, Metabolic Endocrinology and HIV.

Glenmark Generics receives tentative approval for zolmitriptan GLENMARK Generics Inc, USA, the US subsidiary of Glenmark Generic Ltd, recently announced that the US FDA has granted tentative approval for zolmitriptan orally disintegrating tablets, its generic version of AstraZeneca’s Zomig-ZMT® tablets. The tentative approval is for the 2.5 mg and 5 mg orally disintegrating tablets of zolmitriptan and constitutes one of the first tentative approvals granted by the FDA for a generic version of the drug.

Ranbaxy recieves USFDA approval of CIP-Isotretinoin NDA RANBAXY Laboratories Inc has recieved US FDA aproval for Absorica™ a novel, patented brand formulation of the acne medication isotretinoin, developed by Cipher, for the treatment of severe recalcitrant nodular acne. Cipher Pharmaceuticals Inc, Canadian firm, Ranbaxy is expected to launch Absorica™ in the US in Q4 2012; as per the agreement, Ranbaxy will pay royalties on net sales to Cipher.

Marken opens office in South Korea and a cord blood collection service in US MARKEN, a global clinical supply chain service provider, recently announced about its new comprehensive service to collect and deliver cord blood from US and Latin American hospitals to storage facilities in the US. Cord blood samples need to be delivered within 48 hours from time of birth to the final storage destination while maintaining a temperature of 4 – 30°C in special packaging. This new service offered by Marken covers the US and countries in Latin America. Wes Wheeler, CEO, Marken, said, “We are very proud to announce this new service. The collection and special handling of cord blood is very personal for new mothers and their families. We view this as a perfect additional service to offer our increasing number of healthcare clients as we continue to grow into the diagnostic sector.”

Marken recently also opened its first office in South Korea. Korea represents a large and growing base of clinical trials, pharmaceutical companies and pharmaceutical manufacturing centres. The new office is managed by Linda Kim, a specialist in clinical logistics. Wheeler added, “We are pleased to finally have a permanent location in Seoul. We have recruited Linda Kim to manage the customer service operations, manage our suppliers and partners in the country and establish Marken’s name as an important international supply chain services company for the pharmaceutical community. We expect to see continued growth in clinical trials in Korea but more importantly we see an opportunity to help our clients with time and temperature sensitive drug product and active ingredient, which are biologically manufactured.”

Daiichi Sankyo and Ranbaxy launch hybrid business model in Venezuela DAIICHI Sankyo Company, Ltd (Daiichi Sankyo) and Ranbaxy Laboratories Ltd (Ranbaxy) recently announced that Daiichi Sankyo’s subsidiary Daiichi Sankyo Venezuela SA (Located at Caracas, Bolivarian Republic of Venezuela, hereafter Daiichi Sankyo Venezuela) would begin marketing products of Ranbaxy in Venezuela as part of the hybrid business model. Till now, Ranbaxy has been marketing the products

in Venezuela through a local distributor. Daiichi Sankyo Venezuela will now take over this role. To kick off the new arrangement Daiichi Sankyo Venezuela has already started the promotion of Ranbaxy products starting this month. The Venezuelan pharmaceutical market is the third largest in Latin America. Daiichi Sankyo has started its business in Venezuela prior to other Japanese pharmaceutical

companies and has built its presence with innovative pharmaceuticals such as the hypertension medicine Benicar® (olmesartan medoxomil). Daiichi Sankyo will now also focus on expanding Ranbaxy’s portfolio of medicines to promote the hybrid business model, encompassing both innovative and established pharmaceuticals to expand and strengthen its presence in Venezuela.


Modern Pharma•1-15 July 2012

News, Views & Analysis

Brazil - India can make drugs at affordable prices: Sharma ANAND Sharma, Union Minister for Commerce, Industry and Textiles, led a delegation of officials, CEOs, Federation of Indian Chambers of Commerce and Industry (FICCI) leaders and pharmaceutical companies, in Sao Paulo from June 13-14, 2012. Sharma participated in the pharmaceutical roundtable, which covered a wide gamut of issues. He invited companies from Brazil to invest in India`s national infrastructure, manufacturing in SEZs and the food-processing sector. India has plans for one trillion dollars investment in the infrastructure sector over the next five years to build roads, ports, airports and highways. In the pharma field, he explained Brazil and India could further strengthen their ongoing cooperation in making drugs and medicines available

at affordable prices. Sharma stressed that the provision in TRIPs of invoking the route of compulsory licensing for making available cheaper drugs, though introduced at the behest of developing/under-developed countries, was in fact used more

Indian pharma companies raised the issue of requirement of multiple testing despite having approvals from regulatory agencies in developed countries.

often by developed countries. As to India, in March this year, Hyderabad-based Natco Pharma was allowed, following the process of adjudication, and thus not an executive

Sanofi voted leading pan-European quoted company for investor relations SANOFI was recently granted the award for ‘Leading Pan-European Quoted Company for Investor Relations’ in the 2012 Thomson Reuters Extel Survey. The survey highlights achievement across companies listed in Europe. For the third year in a row, Sanofi was also voted first in the European pharma & biotechnology sector and first among CAC 40 companies. “This Extel award is a fantastic achievement for Sanofi and reflects the considerable efforts by management and the IR team to actively engage with the financial community. We thank investors and analysts for their votes,” said Christopher A Viehbacher, CEO, Sanofi. “Our award recognises the high-quality dialogue between the company and the financial community and underscores Sanofi’s commitment to excellence in IR.”

Elder Pharma launches anti-fungal drug in India ELDER Pharmaceuticals recently launched Zalain in order to treat fungal skin infections. Elder Pharma said that it has launched Zalain in association with Ferrer, Spain-based drug firm. According to Alok Saxena, Joint Managing Director, Elder Pharmaceuticals Ltd, Zalain has been introduced in India as part of company’s strategy to strengthen its antiinfectives division that stood at about ` 113.61 crore in FY 2012 and contributed 10 per cent to the total revenue. Further, the company is also planning to launch up to five nutraceutical products in India through partnerships with international firms in next six months.

invocation, to manufacture and sell in public interest cancertreatment drug Nexavar at a price over 30 times lower than charged by patent-holder Bayer Corporation, under Compulsory Licensing (CL). During the discussions in the roundtable, Indian pharma companies raised the issues of requirement of multiple testing despite having approvals from regulatory agencies in developed countries, delays in registration of products in Brazil/issue of import licences as also port clearances; insistence by Brazil in respect of new molecules on reference price in India (where costs are less) than a higher one (as would be necessary given high costs of factors of production in Brazil), etc. Sharma also welcomed the soft launch of the CEOs forum and the first meeting between the Indian and Brazilian Chairs of this Forum during the visit.

In Brief Lupin receives FDA approval for antibiotic capsules LUPIN has received approval from the US health regulator to market its Suprax capsules, used for treating bacterial infections, in the American market. The company’s subsidiary, Lupin Pharmaceuticals Inc, has received New Drug Application (NDA) approval from the USFDA for Suprax (Cefixime) capsules in the strength of 400 mg.

US firm sues Zydus Cadila subsidary A complaint for infringement of patents with regard to drug for treatment of acne has been filed against Zydus Pharmaceuticals USA, Inc, a subsidiary of Cadila Healthcare Ltd (Zydus Cadila) in a district court of US. This complaint has been filed by Arizona-based Medicis Pharmaceutical Corporation (MPC). Zydus USA has been accused of seeking approval from the US FDA to commercially manufacture, use, and selling of a generic version of solodyn minocycline hydrochloride and extended-release tablets, before the drug’s patents which is with MPC, expires.

Lilly expands Chinese generic interests LILLY will be expanding its strategic partnership with Chinese manufacturer Novast to serve Chinese patients with high-quality branded generic medicines. Lilly will increase equity position in Novast by $ 20 million. Novast will set up a platform to supply Lilly-branded generic medicines. Lilly expects its expanded collaboration with Novast to greatly enhance its efforts to build a portfolio of Lilly branded generic medicines in China.

13


Modern Pharma•1-15 July 2012

14

News, Views & Analysis

Bruker announces the new ultrafleXtreme mass spectrometer BRUKER’S market leading, top of the range product has been significantly enhanced to offer both increased analytical power and entirely new functionality, extending the applications far beyond the conventional concepts of what is possible in molecular histology, glycoprotein and biopharma analysis.

UltrafleXtreme

Already the acknowledged leader in Mass Spectrometry Imaging (MSI), the next-generation ultrafleXtreme system incorporates the Bruker patented smartbeam™ laser, now with up to 2 kHz repetition rate with true-pixel image resolution at 20 μm for proteins. This development marks a new milestone in the pioneering smartbeam

laser technology, designed and manufactured exclusively by Bruker for unmatched performance in MALDI mass spectrometry. “Precise intact biomolecule data at the speed and simplicity of MALDI analysis with full glyco-structure reporting really completes the picture for our biopharma customers,” commented Dr Laura Main, Biopharmaceutical Market Manager, Bruker Daltonics. The ultrafleXtreme has also become the industry trendsetter in tools for biopharmaceutical characterisation with patented TopDown T3-Sequencing for revealing terminal modifications, PostTranslational Modifications (PTMs) and sequence impurities. Bruker now presents its rapidly expanding biologics customer base with high resolution intact bio molecule analysis on the new ultrafleXtreme platform. Achieved using the new ultrafleXtreme FlashDetector™, this intact protein bioanalytical ability represents a paradigm change for biologics discovery, development and QC.

GastroPlus™ simulation software program to enhance oral cavity dosing SIMULATIONS Plus, Inc, a leading provider of simulation and modelling software for pharma discovery and development, recently GastroPlus announced that it had signed a collaboration agreement with a top-5 pharma company to extend and enhance its oral cavity dosing model within its industry gold standard GastroPlus™ simulation software program. Walt Woltosz, Chairman and CEO, Simulations Plus, said, “We are pleased to announce this collaboration, which will extend and enhance the GastroPlus simulation model for drug dosing in the oral cavity, such as sublingual, lingual and buccal (inside the cheek) dosing through a variety of dosage forms. These agreements will continue to extend the competitive advantage of our GastroPlus program, adding industry leading capabilities

Knome announces early access program for knomeCLINIC™

KNOME, Inc, recently announced the start of its early technology access program for knomeCLINIC , a software suite designed to help medical researchers and clinicians interpret human genomes for biological relevance. Clinics accepted into the early access program will be given installation priority, access to pilot programs and pre-release prototypes, and the ability to influence knomeCLINIC’s feature set upon general release. On release, knomeCLINIC will consist of kGAP™, a robust, scalable and extensible informatics and annotation platform that serves as the technical

foundation for knomeCLINIC’s desktop interpretation-support applications. Desktop interpretationsupport applications that allow medical researchers and clinicians to identify the genetic variants, genes and pathways that underlie disease and tumor growth; knowledge database, a database of Knomecurated and harmonised reference data from more than a dozen sources, containing over 100,000 genotypephenotype associations and curation applications, software that enables researchers, physician practice groups, and medical institutions to curate and prioritise genotype-phenotype associations, whether publically available or self-generated. “The shift to integrate whole genome information into clinical diagnosis and patient management is evolving rapidly, driven by steadily falling sequencing costs and improved understanding of actionable genetic data,” said Martin Tolar, CEO, Knome. “We are excited to begin collaborating with top-tier medical institutions,” Tolar added.

Bosch showcases new rod insertion and labelling machine for syringes BOSCH Packaging Technology recently presented the new rod insertion and labelling machine RIL 3060B. Bosch has developed its well-proven RIL series. The new RIL 3060B model offers fast handling and is equipped with an integrated backstop assembly that significantly increases

the safe usage of syringes for end-consumers. The syringes are delivered to the rod insertion and labelling machine from the filling line and a plunger is inserted. This is performed by gently inserting the rod into the plunger without moving it. With the new integrated backstop assembly, an additional backstop can

be automatically attached to the syringe flange. Backstops are used to protect the plunger from being pulled out of the barrel, for instance during retraction, and to improve syringe handling during administration. The backstop assembly station substantially improves the handling of syringes and ensures increased safety for the end user.

without the need for Simulations Plus to fund the development directly. These will include rapid-dissolving tablets, solutions, suspensions, oral sprays and buccal patches. When it is appropriate for a particular drug, oral cavity dosing can have significant advantages over traditional swallowed oral doses, including more rapid absorption and onset of action, and reduced loss of drug due to first-pass metabolism in the liver.” John DiBella, VP - Marketing and Sales, Simulations Plus, commented, “The funding support we will receive will add to our steady growth in software licensing revenues.”

Merck Millipore Muse™ cell analyser wins red dot design award MERCK Millipore, the life science division of Merck KGaA, of Darmstadt. Germany, has received the red dot Product Design 2012 award for its product the Muse™ cell analyser. Red dot is one of the world’s largest and most prestigious design competitions from Germany, and is one of the most sought-after quality marks for design recognition globally. The Muse™ cell analyser system, which was launched in 2011, expands researchers’ accessibility to realtime quantitative assessment of cell concentration, cell health, apoptosis, and cell cycle with comparable accuracy and precision to traditional cytometry instruments. The red dot jury recognised the Muse™ cell analyser for its high design quality within the

life science and medicine category. The international jury judged the Muse™ cell analyser on its level of innovation, functionality, ergonomics, longevity, appearance, ecological compatibility and manufacturing approach. “We are extremely proud that the Muse™ received the prestigious red dot award,” said John Sweeney, Head - Life Sciences business, Merck Millipore. “The Merck Millipore design team worked hard to deliver unique benefits with Muse™ that incorporates key attributes such as novel, intuitive software, touch screen interaction, speed and a low cost platform that our research customers were seeking when analysing cell lines within the laboratory.”

Spraying Systems’ new generation technology SPRAYING Systems Co announced the release of the next generation of anti-bearding technology aimed at reducing material build-up on spray devices used in pharmaceutical spray-coating applications. During spraycoating operations, the coating material being applied tends to accumulate on top of the spray device and can lead to poor uniformity of the coated product, process downtime due to clogged nozzles, and wasted coating material. In response to this widespread problem, Spraying Systems has developed its new P-Series antibearding spray set-ups for its VMAU line of spray nozzles. The P-Series set-ups feature a new air cap with high-impingement fan

Anti-bearding spray set-ups

jets and a reduced surface area and is capable to perform the same spray applications for longer with less overall product accumulation and without clogging. After extensive testing it was concluded that the new P-Series set-ups performed better under the same set of test conditions than the earless or hornless designs currently available and proved to be far superior to other technology.


Modern Pharma•1-15 July 2012

CEO Roundtable

15

Distinguished panelists with Team MPh

Future trends in the Indian pharma industry and the role of media to bridge the need gap With the Indian life sciences sector growing in double digits, a favourable policy framework will enhance its prospects. Further, we need leaders and not just CEOs to lead the industry and the country. These were some of the strong sentiments that stood out during the recently concluded CEO Roundtable hosted by Modern Pharma. Edited excerpts... Arshia Khan, Chandreyee Bhaumik and Parita Dholakia arshia.khan@infomedia18.in

he CEO Roundtable was presided over by Sandeep Khosla, CEO-Publishing, Infomedia 18 Ltd, and had participation of some eminent industry gurus. It included the likes of Dr Ajit Dangi, President and CEO, Danssen Consulting; Dr Deven Parmar, CEO and Medical Director – Americas, Karmic Lifesciences; Gaurav Malhotra, MD and CEO, Patni Healthcare Pvt Ltd (PHPL); Dr Manish Gupta, VP - Operations, PHPL; Rajendra Pratap Gupta, President, Disease Management Association of India; Vikram Gupta, Founder and MD, IvyCap Ventures Pvt Ltd and Susan Josi, Managing Partner, Sorento Healthcare Communications Pvt Ltd. The Roundtable was kickstarted with issues facing the Indian pharma, and the present policy framework topped the list of action plan. Dr Dangi initiated the discussion by providing a bird’s eye view of the situation and highlighting the loopholes, while Rajendra P Gupta cited practical solutions to resolve the same. He emphasised, “Questions posed to the industry require practical answers and solutions. Under such circumstances, one can find good receptiveness. And not just receptiveness, if one continues pursuing the right solution, he/she will eventually be able to address the issue at hand. That is where the media helps.”

T

He continued, “Give our policymakers a point which is a real action point, because if you give them 60 page pointers, none will get done; because they are not used to dealing with thick books. This will give them a roadmap from which they can get a political viability.” According to Rajendra P Gupta, media can help by citing case studies of successful business models. As P K Taneja, IAS, Commissioner - Health, Government of Gujarat, said, “Give me successful models. The government is conservative in spending money for detailed analysis and media can help here; it can come up with cases that can be highlighted.”

At a glance Discussing the oft-noticed trends in the pharma industry, Dr Dangi mentioned, “Pharma R&D is moving from chemistry to biology. This year 40 per cent of the new drugs approved by US FDA are biologics. And India’s strength lies in chemistry. Thus, we have to change our skill set. Further, the drug discovery cost has ballooned to $ 1-2 billion but the productivity has declined by almost 60 per cent. So, this blockbuster model is gradually coming to an end. Agreed, Dr Parmar, “If Indian pharma needs to figure in the list of global pharma, it has to focus on innovation.” According to a study by PricewaterhouseCoopers, by

2020 the pharma industry will cross $ 50 billion. And if we are at $ 20 billion and want to reach this ambitious goal, then we need to find out what we need to do to explore the strategic growth drivers. As per the experts, the three priority areas should be: 1. A substantial and good pricing policy by the government 2. Focus on R&D, ie, discovery research 3. A strong Intellectual Property Rights (IPR) environment Continued Dr Dangi, “All this can be achieved through a proper innovation ecosystem that is lacking in India due to the lack of strong IPR and its enforcement. This can be achieved only if the literacy level in India is increased as this will bring about Responsible Self Medication (RSM), which will favour Over-The-Counter (OTC) policy, which is not present in the country at present. More importantly, what India lacks is the skilled talent set for discovery research that will take care of forward engineering, as reverse engineering is passé now.” Solutions that can take care of such problems also lie in the deep rooted educational system. Mentioned Dr Dangi, “This will be achieved only if we have good training institutes with contemporary courses. And in this regard, media can play an important role in changing the mindset of the bureaucracy. Further, the Indian pharma industry comprises multinationals,

India’s big pharma players such as Ranbaxy Laboratories, Dr Reddy’s Laboratories, etc, and SMEs - all of whom have different perspectives. Therefore, we need a federation of all associations.” We need to practise ‘Prevention is better than cure’. For this we require vaccination, immunisation, sanitation, hygiene, clean drinking water, nutrition, cessation of bad habits, pollution control, etc.

Next steps to take Speaking about the challenges facing the industry, Malhotra said, “Today, we face numerous challenges in terms of manpower shortage, infrastructural issues, lack of fast track government approvals, tax incentives, etc. The government should empower better affordable

Dr Dangi

L-R: Dr Parmar and Malhotra

healthcare by incentivising the infrastructure and rest can be taken care of by the private players.” He cited an example and mentioned, “In India, we perform 50 lakh procedures for cataract; however, in China it is only one lakh. Both the countries have same population. Then why India conducts more procedures compared to the other countries; the main reason being that at one point of time the procedures cost $ 400-500. Then, the players focussed on indigenous manufacturing and they came with low-cost ones at $ 10-20. Today, the reach is tremendous. Lifestyle diseases are increasing and the cost of treatment has also gone up. We have live examples to replicate.”


Modern Pharma•1-15 July 2012

16

CEO Roundtable

He also mentioned the recent cut down in prices by Cipla on cancer drugs. All industry stakeholders have to work closely and sort out this problem. Malhotra continued, “Ultimately companies have to see whether they can just bring the products to India or they will have to come up with a market appropriate approach. For this to materialise, the government should support the industry. We must remember 5As of healthcare viz, accessibility, availability, affordability, awareness and assurance of quality healthcare.”

Policy paralysis and beyond Rajendra P Gupta focussed on factors ailing the current policy framework and what more can be done. He said, “Clarity is needed from the policy point of view. There are lot of issues. If one looks at the healthcare system 50 per cent is hospitals, 25 per cent is pharma and 10-15 per cent is diagnostics. And the biggest issue is lack of clarity. Even today, healthcare is accessible to only 35 per cent of the population and when this figure increases the industry will also be doubled. I believe that there is a level of distrust. When a company approaches a policy maker for a Public Private Partnership (PPP) project, the impression is that the company has a profit-making motive. If the government rejects the proposal, then

the money goes back to the government as unused funds. This distrust can end only when there is an increased level of interaction between the industry and the government. Even today the government believes that the private players are here to make profit. This attitude needs to change.” He added the example of the in-news National Rural Health Mission (NHRM), “NRHM is a positive step but the quality of medicines being offered need to change. In rural India there are two issues that need to be addressed; health of the earning member and the education of the children. Free medicine will kill our country. There will not be rational use of medicines. Thus, we need to find out whether universal healthcare will work in our country and if so then in what form.” Taking the discussion forward, Vikram Gupta affirmed, “We are looking at a fundamental shift in power and I see that happening very soon. There are a lot of opportunities in this area. We just have to follow the right approach in a structured way. In such a scenario what we as professionals and you as media have to do is underline and highlight the potential growth areas despite these challenges. Among the various issues are accessibility and affordability of healthcare by the rural masses. All these areas are actually opportunity areas; the

onus is on us as to address these and make the most by attracting more investments and entrepreneurs. The phase that we are going through is a very interesting one as there are a lot of fundamental changes happening, and the consumer is increasingly becoming more aware.” The optimistic tone of Vikram Gupta received a good appreciation among industry veterans like Dr Dangi.

Targetting the bulls’ eye All panelists agreed that we have to target and address the core challenges. Josi explained with the help of examples, “GE healthcare has launched portable ECG machines for the rural India. It has indigenisation and portability on top of its mind, which is a very good approach. Then Dr Devi Shetty (Narayana Hrudalaya) who is setting up a hospital in Cayman Islands, USA, which caters to the people who cannot afford a high cost of healthcare. We often hear that people do well in Silicon Valley due to the environment there, but there are a lot of people who are here and still thinking of bringing about a change there. So they are not only converting the challenges into opportunities and moulding the entire ecosystem but also graduating from it slowly and steadily. That is what we should harness from them. Thus, we have to drive home the change in spite of these policy challenges and change will happen. If the

L-R: Vikram Gupta and Josi

L-R: Dr Manish Gupta and Rajendra P Gupta

message goes from a positive side like the media we have to be optimistic and get things done. Media should start taking charge of things and then there will be a visible change. It is also important to see who is guiding the change.” This highly interactive session brought forward certain innovative ideas to help the industry and the participants enthusiastically discussed the current Indian pharma scenario.

The need of the hour is to have changes in policy, outlook and probably the guiding members to ensure that the Indian pharma industry continues on the success path. In this regard, the importance of good groundwork cannot be overemphasised, and the role of media assumes paramount significance in bringing about a positive change to provide a booster dose to the Indian pharma industry. Photograph: Joshua Navalkar


Modern Pharma•1-15 July 2012

In Conversation With

17

The man of all seasons What can one say about an 87-year veteran, who is the founder of an 800-crore empire, rides in a Rolls Royce Phantom, and is the game changer for the Indian pharmaceutical industry? That he is humble, soft spoken, enthusiastic, down-to-earth, laughs freely – are not some of the traits that may come to your mind. But this is how I gathered Indravadan Modi, Chairman, Cadila Pharmaceuticals Ltd, to be in this free-wheeling conversation.

Parita Dholakia parita.dholakia@infomedia18.in

Known for his timely routine and early waking hours (3.30 am), it was no surprise that the interview started a few minutes before the scheduled time at the corporate office of Cadila Pharmaceuticals located at Bhat, Ahmedabad. Looking at ease with a few well-known brands of Cadila (Polycap, Rabeloc) in his hands, recorder at his side, and a constant flashing camera, when Indravadan Modi, sat down for this interview, he had questions about the magazine, the publication house, and the likes. With a smile that seemed to reflect his calm nature, he listened with interest to all the replies. Before talking about the pharma industry, the octogenarian enthusiastically talked about his charitable hospital ‘Kaka-Baa’ set at his hometown, Hansot near Bharuch, and explained with moist eyes how much his mother’s parents (whom he called Kaka and Baa), who raised him, means to him. Success is sweet but the secret is sweat While riding a stretch of over 40 kms on his bicycle to sell medicines, he might not have thought about the success he would achieve, but never for once he pondered over failure. Ask him about what back up plans he had in mind if Cadila were to fail, and he says none. “There was no alternative for me to fail. We did face failure like every start-up does, but we never gave up. We did not have labourers, hi-tech equipment, but what we had was a vision.” In 1995 when the company was split into two, Modi relentlessly continued the upheaval task of working towards his set target of bringing affordable quality products and with the help of his son (Dr Rajiv Modi), he has achieved a lot. “When we split the company in 1995 - it was the

toughest time for Cadila. We did not have enough resources to continue the operations, but we sailed through. Our USP lies in the fact that we have given the country something unique every few years since day one.” While talking about his biggest achievements he talks with great pride about Cadila’s product ‘Polycap.’ One can notice a hint of fatherly love. He goes on to describe the very firsts of Cadila, the molecules in pipeline, and how the company is relentlessly working on cancer vaccines. If you had to change a few things from the past, what would they be? “Nothing! It has been perfect. I strongly believe that things are as we perceive them to be. Wrong decisions may have been made but one needs to know how to get through them and take them in their stride.” Ask him about his role model and pat comes the reply, no one. He cheekily admits that on being asked this question he says, “I M (his initials). That is, I am my own role model.” Beyond the boardroom In the book ‘Fountainhead’ Ayn Rand has described Howard Roark as a creative genius, an energetic young man who was set to change the world with his self worth. Modi, similar to Roark’s character, is an energetic young (he is 87-years-young) man who is a freethinker of today’s time, and has discovered new truths and capabilities only after being mocked by society, facing failures and then achieving the impossible. His vision to start a pharmaceutical company in days of steel, cloth and grains, to not study food technology (for which he had received a scholarship), and his ambition to do something for changing the healthcare scenario of India have all been achieved. Nothing was done overnight and he stresses that young entrepreneurs too should not fear hard work. Does he believe in lady luck? He smiles triumphantly in a positive and

Photograph: Sharan Goel

says, “Luck exists, yes. But luck is like lock and effort is the key.” To cite it better, he adds a humorous example and says, “Luck is like being offered to eat ‘ladoo.’ But to eat that sweet delicacy one will need to make the effort of opening his/her mouth.” “God has been kind to me; who will not believe in the existence of a mighty superpower?,” he adds with the signature smile. The tough veteran has scaled the highest mountain amid some treacherous path and visited Kailash Mansarovar five times! He willingly shows me a rare picture taken from the camps and admits his desire to go there again. Ask him about his favourite destination and he admits that in spite of visiting over 60 countries, he would have hardly thoroughly seen a few. “You know how Gujaratis are. When I visit a country, I check in to the hotel, attend the scheduled meetings and go back to the airport. Never for once I would have stayed for more days than required. There have been times

when I had to travel to Bombay (now Mumbai) and I used to take the morning train and return the same day. I have also bathed in some of these trains to save time and hotel money. I am miser when it comes to spending money for unnecessary things like bottled water, but my R&D investment and other such humanitarian causes see no spending limit. I do not want to reduce my R&D investment, and that is one of the reasons why we are not going for an IPO.” Simplicity reeks out as he provides snippets from his life, and I ask him what his prized possessions are. He says nothing. On citing how a first car or the watch he is wearing (Omega) can be prized possessions, he says, “I am not into materialistic things. Even today, when people buy things for me or get me expensive clothes, I ask them, what is the need?” Ground-breaking efforts and ground-touching feet With his son now running the show, Modi is not too

Quick tips for the young No shame in labour For your benefit, never cheat your customers Look for good/God in everyone. If someone does bad with you, it probably is God willing National spirit is the first spirit; do not put country’s interest before anything else

actively involved with the company. With hobbies of horse riding, harmonium playing, bhajan singing, book reading (currently he is reading ‘Savitri Gunjan’ by Ambalal Purani), he is all set for a new inning in his life, as he says “All my efforts currently are on developing a spiritual side.” A strong believer of the fact that the Indian pharma industry would have been some 20 years behind its present time had it not been for Cadila Pharma, Modi insists that even in the near future Cadila would have paved way for several such feats of the industry, “India has proved its name as far as the generic market is concerned. In the near future, India will be able to give new molecules to the world and Cadila has started the trend.” To capture a little from the world of Indravadan Modi, and take some magic along – was the agenda of this interview. Apart from that, we achieved the realisation that there is much further than the boardroom and success is not all about numbers and breaking even. One needs to have integrity, dedication and passion to achieve stars, and he has shown us how.


Modern Pharma•1-15 July 2012

18

Special Focus

Recent advances in the pharma cold chain

The need to get tech-savvy Cold chain is a segment within the pharma industry, which is of critical importance. Over the years the pharma industry has expanded and so has the export of drugs to other nations. This in turn has increased the need for a better and stronger cold chain system. We discuss the current scenario and the developments in this field.

Jasleen Kaur Batra jasleen.batra@infomedia18.in

old chain for pharmaceuticals needs to be temperature controlled as the shelflife of the products needs to be maintained. A well organised cold chain system has the capability of reducing the deterioration of drugs as well as retaining the quality of the product. Today, the Indian pharmaceutical industry is valued at $ 22 billion with experts projecting the market to grow at a Compounded Annual Growth Rate (CAGR) of eight per cent during 2010-14. Indian pharma exports are poised to grow at 30-35 per cent during 2011-2012 and are projected to touch $ 15.8 billion in 2013-14, according to the Indian Drug Manufacturers’ Association (IDMA). With this, the exports have also grown. Hence, the cold chain segment is of critical importance as the pharmaceutical compounds being exported have the likelihood of getting damaged with excessive heat or freezing during shipment, resulting in reduced efficacy.

C

Although common temperature range for a cold chain in pharmaceutical industries varies from 2-8 °C, when it comes to specific temperature tolerances the levels largely depend on the actual product being shipped. According to the GMP guidelines all processes that might impact the safety, efficacy or quality of the drug must be validated, including storage and distribution of the drug substance. Hence, the need for a well-established cold chain distribution process, especially for pharma products. Today, a number of countries import vaccines along with other forms of drugs from India. The process of shipping drugs from one place to another requires careful consideration, design, validation, and supervision at all levels considering various factors such as the type of shipping containers to be used, the distribution carriers to be contracted, what humidity control equipment is required (if any), the types of environmental conditions that the drug is expected to maintain, the length and time of the distribution route and more. Due to the above listed factors, the packaging must be capable of maintaining product temperature even in case of fluctuating weather.

The current scenario

As the pharmaceutical industry is temperature sensitive, it is of critical importance that all the components of logistics are in place. Avtansh Agarwal Partner & Managing Director, Cold Chain Consultants India Pvt Ltd

“The main aspects that one needs to look at in cold chain for pharma products are storage and transportation. As far as storage is concerned, what most companies do is have an in-house cold warehouse, wherein they meet the regulatory and technical requirements of the product and ship the drugs accordingly,” says Avtansh Agarwal, Partner & MD, Cold Chain Consultants India Pvt Ltd. However, explaining the intricacy of cold chain, he further adds, “As the pharmaceutical industry is temperature sensitive and all the vaccines and medicines need to be maintained at a certain temperature, it is of critical importance that all the components of logistics are in place.”

requirement of the drug to ensure that the temperature range is maintained. Hence, the moment the product leaves the factory the drug is packed in active container and the packaging is maintained in the same containers till the time the product reaches the desired location. This kind of packaging service is a recent advancement and has helped the pharma industry to a great extent.” All these factors have helped improve the state of cold chain in India but even today India is at a very nascent stage as compared to other countries and has a long way to go.

Constraints within the cold chain

Photograph: Mexy Xavier

Over the years due to the increase in the number of exports of vaccines to the other nations, the state has improved from what it was a decade back. An important advancement that has taken place over the years is in terms of awareness. Earlier, most of the Indian companies were unaware of what cold chain is and what temperature needs to be maintained while shipping a drug from one place to the other. However, with globalisation and number of MNCs coming to India and setting up their units in India, the awareness has increased. Most of the companies are now aware of the cold chain process and what it comprises. This has helped the Indian pharma industry in ways more than one. The MNCs have also created accessibility to state-of-theart cold chain services. Today, if a company is willing it can contact an MNC or any other logistics provider and get their product shipped according to the right standards. Packaging and technology too has witnessed an augment

over the years. “Today, the solutions that a few companies provide in India are technologically superior to what was being provided 5-8 years back. Initially, the industry was using passive cooling boxes but now they

The Indian logistics companies need to indulge in more innovation and invent better technology and packaging solutions keeping in mind the requirements of the Indian pharma. have graduated from that to dry ice solutions, ice solutions and further to gel-based solutions. Hence, the industry has been moving upwards, but at a very slow pace,” informs Agarwal. Adding to this he says, “In shipping systems there are two types of packaging - one is thermocol and the other is an active container, which is battery operated and cools/heats the product depending on the

Inspite of the advancements, there are a few factors that are creating a hindrance in the development of the cold chain sector in pharma. One of the biggest hurdles is that of cost. The reason why a number of companies do not opt for sophisticated cold chain systems is due to its high cost. However, it is important that people evaluate this situation critically. If a company does not follow the desired cold chain system while transporting a drug, it is likely that a few of the drugs would get damaged. As the damaged drugs are returned by the costumer, the company definitely experiences a situation of loss. But, if a company invests 20-30 per cent more than the usual in a state-of-the-art cold chain system the probability of a damage in the drugs are bleak, which would in turn benefit the pharma company. Advancement with regard to packaging and technology is another quandary faced today. Although over the years, the state of technology in cold chain has improved, the growth is very slow and negligible. The Indian logistics companies need to indulge in more innovation and invent better technology and packaging solutions keeping in mind the requirements of the Indian pharma companies. Today a number of pharmaceutical companies export their products to countries across the globe. For them to flourish further and create goodwill for themselves it is important that the quality and effectiveness of the drug be maintained, which can only happen with the support of a strong cold chain system. “I feel that the cold chain pharma sector in India is at an extremely nascent stage today and has a long way to go in terms of getting sophisticated solutions in the market as well as getting the companies to understand what their requirements are and how they can meet them,” concludes Agarwal.


Modern Pharma•1-15 July 2012

Special Focus

Investments in SCM

Is it adequate enough? The pharma industry is increasingly embracing supply-chain as a competitive differentiator. Trends in Supply Chain Management (SCM) practices and the route to market options have begun to change the way business is done. But is the investment enough to sustain the good prospects of the industry?

Chandreyee Bhaumik chandreyee.bhaumik@infomedia18.in

ccording to the McKinsey’s report, ‘Building India: Transforming the nation’s logistics infrastructure’ logistics segment is one of the vital elements of India’s success story for economic development and urbanisation. Recognising its significant role, the Goverment of India has tripled annual spending on logistics infrastructure over the past seven years, from about $ 10 billion in 2003 to $ 30 billion in 2010. However, the report also says that despite this increase, the country’s network of roads, rail and waterways will be insufficient to accommodate a three-fold increase in freight movement over the coming decade. Therefore, building a logistics infrastructure capable of handling rising freight traffic more efficiently will present opportunity for user industries, infrastructure developers and construction companies, among others.

A

SCM in pharma End-user safety, counterfeit prevention and chain of custody tracking are major concerns for pharma companies in India. Clinical trials, on the other hand, require co-ordinated delivery of supplies to sites that are actively recruiting and enrolling patients, while ensuring complete compliance

to statutory requirements. How a company manages its supply chain network can either impede or improve its efficiency and profitability. Talking on effective SCM, S Sridharan, Managing Director, TAKE Solutions, avers, “Collaboration for standardisation of processes, management of network assets and managing product flows can also help in better utilising available capacities, preventing counterfeiting and diversion of controlled substances for illicit purposes. Effective SCM, therefore, not only can ensure compliance and competitive advantage to each firm, it also helps in developing capabilities and utilising capacity as an industry in general.” He adds that pharma supply chain starts with the sourcing of active and inactive ingredients for approved products. Dosages are formulated and packed into various configurations – eg tablets, capsules, injectables, etc. These products flow through multiple tiers across channels in the distribution network – typically including C&F agents, dealers, stockists, retail pharmacies, medical institutions, etc before reaching the end-consumers. He highlights, “There are four important issues from a logistics standpoint – special packaging & handling requirements, velocity, expiry management and chain of custody tracking. As outsourcing of logistics operations increases, service providers are required to address all these issues, and help ensure 100 per cent product availability at the right time, at the right cost, in good condition to the right customers. As a result, logistics costs sometimes account for as high as 55 per cent of the costs in the pharma value chain.”

networks, self-help groups and local entrepreneurs for direct to consumer coverage.” Giving an investment update by the logistic providers, Vineet Kanaujia, VP - Marketing, Safexpress Pvt Ltd, says, “In India, pharma logistics has seen considerable investment since pharma is one of the most vital segments for the Logistics Service Providers (LSPs). Also, globally, the investment scenario is also very positive. Today, approximately onesixth of business revenues come from the pharma segment. We invest a major portion in pharma segment, but it is difficult to give a particular number to it.” Sridharan says, “While greater investments

Adequate input? Supply chain managers in the pharma industry are now selecting LSPs with the same attention that they give to sourcing decisions for key input materials. S Sridharan Managing Director, TAKE Solutions

Today, ensuring availability, preventing brand substitution and enabling market penetration are top priorities for pharma supply chains. As the quest for penetration into rural markets continues, pharma supply chains will innovate to serve consumers in these markets cost effectively. Talking in this context, Sridharan says, “Pharma sector will see innovation for greater integration of the sales force and distribution models to drive the supply chains for rural markets focussing on leveraging existing

Efforts to improve market reach and penetration will drive greater adoption of more efficient supply chain and distribution practices. Vineet Kanaujia VP - Marketing, Safexpress Pvt Ltd

in R&D and growing pharma outsourcing to India will drive more ANDA filings and clinical trials in India, respectively, efforts to improve market reach and penetration will drive greater adoption of more efficient supply chain and distribution practices.”

Building on a relationship Pharma supply chain managers by embracing outsourcing increasingly for competitive advantage, are constantly raising the bar for logistics service providers. On the other hand, the LSPs are gearing up for the challenge by acquiring new capabilities and offering innovative services. Elaborating in this regard, Sridharan opines, “Supply chain managers in the pharma industry are now selecting LSPs with the same attention that they give to sourcing decisions for key input materials. Successful logistics providers are committed to keeping pace with the widening expectations of their customers, and growing with them. Like in any other industry, relationships that are based on building lifetime value, and on ensuring business continuity and growth, tend to be more successful than those based only on service level agreements.”

Looking ahead According to Sridharan, while all other activities now conform to pharmaceutical good practice guidelines, the element of warehousing, transportation

19

and distribution is perhaps one of the ‘weak links’ in the supply chain. Successful companies therefore employ qualified LSPs and closely monitor these activities through use of IT. He highlights, “Indian pharma distribution differs from that of the developed world in one major area – it is largely served by the unorganised retail sector. While this is something that the government and the industry would like to remedy, supply networks today are tiered, difficult to manage, and intermediaries tend to take their share of the margin.” Kanaujia says, “In pharma we require a challenging distribution model. One of the biggest threats to the pharma industry is spurious and counterfeit drugs. For this scenario to improve, the entire mindset has to change. Even today, there are several pharma companies that have not adapted to the organised SCM services. When a company embraces an organised LSP, chances of counterfeits become close to zero. Sometimes, it is not about one or two cartons but the entire truck goes missing and it is replaced by a drug with spurious drugs. Further, majority of the pharma products do not have bar-coding. This is a serious concern.” He adds that even for cold chain services, one must remember that it is an

Pharma supply chain managers by embracing outsourcing increasingly for competitive advantage, are constantly raising the bar for logistics service providers. end-to-end process right from production, referee trucks, final point, temperature control at the retail point, etc. Thus, any sort of power cut is a hindrance in this respect. Talking about the future ahead, Kanaujia says, “Investment is already happening and that is definitely going to increase. But what is more important is the change in the mindset towards organised logistics.” Organised retail in the Indian pharma industry is at a nascent stage compared to the developed world. Dependence on unorganised sector makes it easy for spurious and counterfeit drugs find their way into the mainstream distribution channels. Medical shops in the unorganised sector are also able to avoid sales tax; this being predominantly cash business. Drugs are sometimes also stored in sub-optimal conditions, making their efficacy questionable.”


Modern Pharma•1-15 July 2012

20

Special Focus: Interface

Cold supply chain acts like a backbone for the pharma industry Jasleen Kaur Batra

blood, tissues, vaccines, antiretroviral and anti-cancer drugs, etc, require cold chain in place for their safe movement.

jasleen.batra@infomedia18.in

What are the opportunities for the Indian pharma logistics with regard to cold chain management of pharmaceuticals? Indian pharmaceutical industry is growing at a burgeoning rate and there is a huge movement in terms of import and export. This gives an opportunity for temperature-controlled transportation of pharma products from airport to the manufacturing facility or from the manufacturing facility to the direct consumer. According to the data published by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, the total turnover of Indian pharma industry in 2011 was $ 21 billion. Out of this total, domestic formulations market was worth $ 8.34 billion and total APIs market was worth $ 3.92 billion. Total export market was worth $ 8.47 billion. Indian exports go to more than 200 countries around the globe including the highly regulated markets of US, Europe, Japan and Australia. In the biotechnology market, exports account for around 65 per cent of the country’s vaccine market and we are a major supplier to organisations such as the UNICEF. The domestic Indian pharmaceutical market is expected to reach $ 55 billion in 2020 at a Compounded Annual Growth Rate (CAGR) of around 15 per cent. The ever growing pharmaceutical industry is acutely temperature and time sensitive. Cold supply chain acts like a backbone for pharma industry. It is a big responsibility to have a regulatory supervision and to maintain the efficacy of the drug throughout the supply chain. Complex compositions, limited shelf-life, large number of intermediaries, statutory compliances stand as challenges in maintaining the quality of drugs. Strict hygiene, safety and quality measures need to be incorporated to keep the medicines fit for use. The pharmaceutical industry opens a plethora of opportunities for cold supply chain management. Not only the produced medicines require temperature-controlled storage and distribution, but the raw materials required to manufacture the medicine, or required for R&D need temperature-controlled movement. APIs, reagents, DNA samples, plasma cells, enzymes,

What lacunae the Indian pharma industry faces when it comes to transporting pharmaceuticals (infrastructural issues)? Indian pharmaceutical industry faces the following challenges:

consumption. Investing in dedicated pharma competence centres enhances our global network as we deliver health for the region and the world. How much the company does invest in upgrading the technology, infrastructure to provide better logistics service to pharma companies? Snowman has ISO 22000 and

Increased efficiency and productivity of the transport system would result in lower transit times. Implementation of GST: The introduction of Value Added Tax VAT) and the proposed introduction of a singular GST are expected to significantly reduce the number of warehouses, which manufacturers are

...says Ravi Kannan, CEO, Snowman Logistics Pvt Ltd. Here, he discusses the role of cold chain in the pharmaceutical industry and the various opportunities that the industry possesses.

Lack of technology for continuous monitoring & transparency in supply chain Lack of pan India organised logistics players adhering to global standards Temperature maintenance is critical during storage and transportation of goods. How can the government help in building strong logistics for pharmaceuticals? Some of the key building blocks, which would help in the development of pharmaceutical logistics include: Providing a dedicated pharma zone near airports and seaports with good inter & intra city connection using all modes. Implementation of Goods and Services Tax (GST) Faster customs/ Drug Controller General of India (DCGI) clearance Measures to upgrade skill sets Strict action on violation of safety standards Implementation of Good Distribution Practices (GDP) is essential for keeping counterfeits out of the legitimate supply chain/ distribution network Asia and other emerging markets are a key sourcing, manufacturing and distribution base for the global pharma industry. Increasingly, they will also be key markets for

ISO 14001 certified state-ofthe-art warehouses located across 16 locations in India. Being an expert in managing cold supply chain, we could provide innovative solutions especially weaved and customised for pharmaceutical industry. We understand the highly sensitive nature of pharmaceutical supply chain and the high degree of hygiene and safety, which needs to be maintained. Our quality standards, state-ofthe-art infrastructure, efficient inventory management, quick and safe movement have been pillars of growth and success for this industry. We could gauge the accurate requirement of the industry and started providing refrigerated transport. Growth drivers for us are: Efficient infrastructure to support pharma chain Adherence to strict quality norms and compliance to food standards All our locations are integrated using our stateof-the-art ERP system, etc. The Indian logistics market has witnessed a growth rate of 9.2 per cent over the past year. What have been the growth driving factors? The primary growth drivers of this industry are: Investments in the infrastructure sector amounting to $ 350 billion.

There is a ‘Pharma Zone’ built to cater to pharma market at the Hyderabad airport. This provides temperature controlled service and handling for more than 30,000 tonnes of pharma products. required to maintain in different states, thereby resulting in a substantial increase in demand for integrated logistics solutions. Robust trade growth: National and international trade is increasing by leaps and bounds. Hence, the requirement for warehousing, transportation and distribution will increase significantly. Multiple global challenges have increased the value of the supply chain flexibility that outsourcing provides. Moreover competition, market integration, increasing regulatory requirements, product security concerns and channel pressures have increased the need for flexible supply chains. Flexibility allows global companies to expand capacities and

locations, lengthen or shorten product verticals, and tap more customers. Growth of Third Party Logistics Players (3PLs): Manufacturing at the world class level with technological advancements are compelling companies to concentrate on their core competencies and reduce their capital/operating cost by outsourcing their logistics function. Hence, Third Party Logistics (3PL) service is bound to flourish in the future as well. What is the new technology support system available for pharma logistics today? Technology integrates the verticals of logistics industry together just as stars are tightly held in a constellation. To reduce errors and increase efficiency, reliable technological systems are required; Radio Frequency Identification System (RFID), holograms, 2D barcodes, data loggers, colour shifting ink, chemically reactive markers, automatic alert systems are essential for the smooth working of pharma cold chain. Frequent technical audits can help the companies to gauge specific technological requirements for their business. Use of shipper boxes for proper handling of sensitive items keeps the products safe and facilitates quick movement in desired volumes. What according to you is the USP of India in terms of cold chain for pharma? Huge consumption market with growing demand and cheap labour has attracted a lot of pharma companies, which find it feasible to produce in India. Opportunity for cold chain players in India is bound to grow. 3PL players have a huge opportunity in terms of providing transportation and storage for such foreign players who want to grasp the urban and rural Indian market. Players who can provide pan India network are sought by these players. Indian cities like Hyderabad, Vishakhapatnam, Bengaluru, Ahmedabad and Delhi have huge pharmaceutical potential. There is a ‘Pharma Zone’ in Hyderabad built to cater to pharma market requirements at the Hyderabad airport. This facility provides temperature controlled service and handling for more than 30,000 tonnes of pharma products per annum. The market opportunities are increasing at a tremendous rate, transforming the Indian cold chain pharma industry.


Modern Pharma•1-15 July 2012

Special Focus: Roundtable

21

Is there a need for SCM standards for transporting dry pharmaceutical products? Jasleen Kaur Batra and Shibani Shah jasleen.batra@infomedia18.in and shibani.shah@infomedia18.in

Hemanth D P

Dr Amita Birla

COO – Hub Development, Cargo and Free Trade Zone, GMR Hyderabad International Airport Ltd

Associate Director - Clinical Operation, Karmic Lifesciences Yes, definitely there is a need for better SCM for dry pharmaceutical products as this is one sector that is not paid much attention to. We believe that if it is vaccine it needs to be transferred at a particular temperature; if it is a tablet it can be transported under any circumstances and temperature. However, this is not the case. Temperature is not given the due importance. Today, before any product is released stability data is established, which includes the temperature, humidity and other factors that the product can withhold. When the product is being transferred and the range of temperature is not maintained, it can also have an effect on the end user. Hence, it is of critical importance that the SCM standards be maintained for dry products. We need to force our regulators to see to it that even this comes under the purview and the dry pharmaceutical products are transported appropriately with the required temperature. However, at Karmic, we ensure that all the standards are maintained at all levels.

The Indian pharmaceutical sector has witnessed an increase in demand for pharmaceutical products due to the demographic shift. To ensure that the needs are met, the Supply Chain Management (SCM) needs to be strong. In this context, do we need SCM standards while transporting dry pharmaceutical products?

Parag Risbud

V Gopalakrishnan

VP - Logistics, Avalon Consulting The Indian pharma sector is expected to grow rapidly. Today, it is nearly $ 18 billion and is expected to reach $ 60-70 billion by 2020. Also, the global pharma opportunity is approximately $ 75 billion, which is growing at a rate of 15 per cent CAGR. With the growing pharma exports the industry is also facing challenges with respect to the SCM system. With the foreseen potential in the bio-pharmaceuticals segment the cold chain segment will further gain momentum. Today, the most important aspect of pharmaceutical logistics is the integrity to monitor and control the temperature of products during storage and transportation from origin to definition. It is the responsibility of all supply chain participants to maintain the safety and efficacy of pharma products. Considering that cold chain requires significant capital investment and also has incurring operating expenses, the viability of expenses on an ongoing business is always a challenge. However, the logistics service providers are gearing up to meet the demands and the regulated protocol. Hence, in my opinion having standards for dry pharmaceutical products is extremely important and the industry is trying to change its approach to ensure the products are delivered in the right quality and temperature.

Any medicine intended for human use or veterinary product administered to food producing animals, presented in its finished dosage form or as a starting material for use in such a dosage form, should be controlled by pharmaceutical legislation in both the exporting and the importing state. Storage conditions for pharmaceutical products should be in compliance with the labeling, which is based on the results of stability testing. Special transport and/or storage conditions should be stated on the label. If a pharmaceutical product is intended for transfer outside the control of the manufacturer’s products management system, the name and address of the manufacturer, special transport conditions and any special legal requirements including safety symbols should also be included on the label. Packaging materials and transportation containers should be suitable to prevent damage of pharmaceutical products during transport.

Counsellor, Confederation of Indian Industry

Surendra Deodhar Head – Material Management, Reliance Life Sciences Pvt Ltd A package during its journey from manufacturer to the consumer may get subjected to various abuses including impact, vibration, pressure, tilt, temperature, humidity, light rays, X-ray and so on. Different formulations react differently to each one of these factors. It is also worth noting that a package gets handled by several people till it is finally consumed. And it is not fair to expect that all these people in the chain to have competence to exercise judgment about handling of packages with due consideration to all the factors. Hence, the need for standards. Packaging solution deployed by a pharma company is not just regulation oriented. But in addition depends on several technical as well as soft cultural aspects such as appetite for risk, strategy to ‘just meet’ or ‘exceed expectations’ of the stakeholders, respect for innovation and so on. It also depends on factors such as the customer profile, rural or urban market. Standards provide a common denominator through all this variety. However, standards per se are not effective, unless backed by measures like training and audits.

Temperature sensitivity is not the only concern in pharma logistics. Besides temperature, there are many other factors like environmental contamination (air, moisture, particulate penetration etc) and optical interference (excess light impact), which even the dry pharma products have to be protected from. Else, their microbiological integrity and pH stability would get affected, thereby making drastic changes to the drug. It would be a risky call trying to address these constraints at the transportation stage, as it involves multiple handling and adverse transport conditions, which cannot be monitored economically. Hence, rather than introducing standards and regulations in transportation of dry pharma products, it should be done within the factory itself, through effective packaging solutions. Else, it would still worsen the logistics cost. If the external temperature is crossing the stability level of the drugs, then it would lead to volatility, thereby affecting its physical and chemical properties. To avoid this, preservatives are added to it after thorough analysis, so as to widen this tolerance level of the medicines. Besides this, there are packaging solutions readily available in the market to provide further thermal protection to the drug. Hence, adding more regulations or stringent packaging conditions is not necessary, as it would just complicate the whole supply chain, rather than adding value to it.

Editorial take For any product to be transported from one place to the other having a strong SCM system is of critical importance. The importance of a proper SCM system increases further while dealing with dry products as the damage may not be visible but the irregularity of the temperature might cause damage to the produce. Hence, it is of critical importance to have SCM standards for dry pharma products.


Modern Pharma•1-15 July 2012

22

Facility Visit

Chandreyee Bhaumik chandreyee.bhaumik@infomedia18.in

he vision of Arshiya International Ltd for setting up Free Trade and Warehousing Zone (FTWZ) is a part of its endeavour to boost operational efficiency. Owning and operating India’s first FTWZ will not only allow Arshiya to bring unique end-to-end solution for its clients, but also create partnership opportunities with technology, supply-chain and international operations companies worldwide. Conveniently located for port or multi-modal hinterland connectivity, the FTWZ facilitates the movement of products in and out of the country. It is an important connect for leveraging India’s cost and skill arbitrage. It further facilitates and empowers one with strategic geographical position to enable one to benefit from this distribution hub. As Ajay Mittal, CMD, Arshiya International Ltd, highlights, “Arshiya FTWZ offers superior infrastructure, operational and regulatory benefits. It further helps in customised storage solutions suited to the products of this sector with HVAC system, chillers, freezers, palletised racking system, etc that offers different storage solutions as per the product requirements. Hygiene, safety, real time cargo visibility, etc have also been of prime importance in designing this facility.” “Arshiya’s first FTWZ got operational in December 2010 at Village Sai, Panvel near Mumbai. This is India’s and Arshiya’s first FTWZ,” underlines Mittal. Spread over an area of 165 acre, the zone encompasses a state-of-the-art facility with 24x7 on-site custom clearance house having world class infrastructure powered with safety, equipment & maintenance facilities. The FTWZ also has Inland Container Depot (ICD) and Container Freight Station (CFS) ICD/ CFS facility with superior safety and hazardous cargo handling capacity of 10,000+ containers.

T

FTWZ security features The FTWZ has Central Operations Control Centre (COCC) to monitor

Reach stacker

A ringside view of Arshiya FTWZ

Arshiya International FTWZ, Panvel

Caring for the people and environment In line with maintaining high standards, safety and efficacy of products (pharmaceuticals) stored here, Arshiya Free Trade and Warehousing Zones (FTWZ) has taken adequate steps to limit the carbon emission from its facility. and control facilities not only of FTWZ Panvel, Mumbai but also of Arshiya’s entire pan-India infrastructure on a 24x7x365 basis from one single location. There is a centralised CCTV monitoring of all warehouses & infrastructure with close to 20 CCTV cameras per warehouse and capacity to store up to 50 days worth of footage. The centralised access control remotely manages and restricts entry to facilities in the FTWZ with the provision to quarantine specific areas within the warehouse. The centralised fire alarm monitoring across all warehouses that is integrated with CCTV, access control & IP telephony to enable real-time fire detection and to notify key stake holders in case of any emergency. Discussing the security feature, Mittal highlights, “The security personnel and supervisory staff undertakes physical checks of all manpower (supported by CCTV systems, access enabled turnstiles) & vehicles (supported by CCTVs, boom barriers) entering the FTWZ. Thus, FTWZ has suitable infrastructure for the pharma sector that offers product safety and offers bespoke storage solutions for the varied requirements.”

Guarding against emergency

Weighing bridge

Arshiya FTWZ knows well how to guard against natural calamities. In addition to warehouses at Arshiya being designed as per Seismic Zone 4 requirements that will

also reduce due to the capability of quality control before dispatch from India.” Thus, Arshiya International through its FTWZ aims to bring solutions to all logistics related issues.

Future ready Understanding the critical need for logistics infrastructure, Arshiya’s another phase of evolution was its foray into asset heavy services with Arshiya rail. Signing off Mittal adds, “Today, Arshiya rail is the second largest private container train operator with pan India operations, 20 rakes, customised containers and private sidings at strategic locations. FTWZ is a trade-related infrastructure

resist heavy earthquakes there are other precautions too. Mittal elaborates, “The FTWZ has a capacity to handle rainfall with peak intensity of 156 mm/hour or 10 cubic metre per sec. Storm water drainage is strategically designed to ensure that there is no water logging in the site. The entire structure of storm water drainage is a combination of Hume pipes and surface drainage. Discharge capacity of the entire FTWZ is more than 5 lakh litre of water per day.”

Benefits galore: Regulatory and operational Based on whether the company is importing, exporting or re-exporting the following regulatory and operational benefits are available to pharma companies their vendors that are not available at any ICD/CFS/ bonded warehouses. Talking about the advantages in import, Mittal says, “Companies can now import in bulk, taking advantage of price fluctuations in the international market as well as reduce the cost of multiple shipments. This can also enable companies convert air shipments into sea shipments. Taxes like SAD, VAT/CST, and stamp duty are exempted for clearance/sale from FTWZ. And for exports products from India entering the FTWZ are treated as deemed export providing immediate export benefits to exporters. Exporters also benefit from local tax exemption (eg CST, sales tax, excise and VAT) on all activities conducted inside the FTWZ. FTWZ rentals, labour, value added services are exempted from service tax. Companies are also able to meet their export quotas by exporting into FTWZ that is a deemed foreign territory. Reverse logistics costs

Arshiya’s first FTWZ got operational in December 2010 at Village Sai, Panvel near Mumbai. This is India’s and Arshiya’s first FTWZ. Ajay Mittal CMD

that greatly benefits importers, exporters & re-exporters and has the potential of leveraging India as a trading and trans shipment hub. Arshiya already has two operational FTWZs, on in Mumbai near JNPT (135 acre) and the second in Khurja near Delhi. Arshiya has also developed industrial and distribution hubs for domestic cargo warehousing, consolidation and movement through rail. First of such hub is operational in Khurja, UP and is a part of Arshiya’s integrated logistics park comprising 135 acre FTWZ, 130 acre industrial and distribution hub and a 50-acre rail siding.”


Modern Pharma•1-15 July 2012

Insight & Outlook: Automation Trends

Sales force automation

Say ‘No’ to manual errors Gone are the days of manual work. With sales force automation, there are fewer chances of errors and optimum utilisation of time is possible. But in a country where infrastructure still remains a big hurdle, can such a system survive?

Chandreyee Bhaumik chandreyee.bhaumik@infomedia18.in

ith terms such as ‘revenue growth’, ‘upping profits’, ‘increasing investment’, ‘marketing strategies’, ‘Return on Investment (ROI)’ catching up, pharma companies are in a constant competition against one another. It is not merely about winning the race but also about offering the best. Thus, today pharma companies are required to continuously make the best use of their respective sales force resources in order to gain progress. In this type of dynamic market, where new competitive threats emerge rapidly, massive changes are bound to exist. It is essential to implement a repetitive and a constant learning model that will enable companies to identify varied market shifts and build response plans in real time and that is also before their respective competitors capture the market share. Sales force automation was initially meant to improve sales force productivity and thereby encourage sales team to document and communicate their field activities. And with time it is becoming increasingly focussed on cultivating customer relationships and improving customer satisfaction. Thus, a sales force automated system automatically tracks all the steps in the entire sales process. It is a technique wherein a software is used to automate the business tasks of sales, including order processing, contact management, information sharing, inventory monitoring and control, order tracking, customer management, sales forecast analysis and employee performance evaluation.

W

Benefits galore Customer is the primary focus for any organisation in any industry. Further, every company certainly invests in marketing activities. And it is extremely important for them to have an ROI. Sales force automation primarily focusses on cultivating customer relationships and thereby improving customer satisfaction. Therefore, this system helps in sales process/

23

providing analysis of the same and plan timely corrective actions based on the analysis. But is India ready to handle automation? Elaborating the prominence of sales force automation in India, Chittaranjan adds, “No doubt there are several benefits, but one needs to note that for sales force automation we need full online connectivity. Without connectivity nothing can function and unfortunately in our country network is still a challenge. Thus, infrastructure needs to improve.” He elaborates that if the sales person from his company visits a pharma company in an interior part of the country there is a high probability that there will not be any connectivity. In such a situation, automated systems cannot operate. Chittaranjan highlights, “With such system 30 per cent of the turnover can increase. There are fewer errors. Sales force automation reduces communication time. Here, we are looking at instant communication.”

Next in line

activity management, which in turn aids in reducing cost of sales. With this system now there would be fewer errors, and less duplication. Discussing the advantages of sales force automation, Chittaranjan, Technical Director, Prama Instruments Pvt Ltd, says, “It can be said that the benefits of sales force automation are unidirectional. It not only helps in customer relationship but also in retrieving information from the sales force that is working. Therefore, there is optimised usage of the productivity of the sales force.” Further, discussing the advantages of sales force automation,

No doubt there are several benefits, but one needs to note that for sales force automation we need full online connectivity. Chittaranjan Technical Director, Prama Instruments Pvt Ltd

G Rajasekaran, Regional Sales Manager and Product specialist (SE Asia), Hi Media Laboratories Pvt Ltd, says, “Sales force automation has a lot of advantages. Earlier, all the work was done manually. But now everything has become organised and classified product wise, customer wise, segment wise, etc. With this, it is possible to get the latest data on daily, monthly and yearly basis.” He highlights, “Sales force automation has several models and whatever model we use has advantages. The entire system of work becomes extremely channelised and interactive.” He cites an example from his own company. He avers, “Everybody in our company is connected by this. With this system in place it is possible to access online reports, give comments, etc.” Sales force automation delivers an on-demand solution that caters to the varied needs of everyone from small businesses to large, global organisations. It provides the entire team with a complete customer view that is shared with sales and support in real time. With powerful and efficient contact management and campaign management capabilities, one can maximise the efficiency of the entire online and offline marketing mix, including search marketing. An integral part of any sales force automated system is company wide integration among different departments.

Further, if these automated systems are not adopted and integrated properly within all departments, there might be a lack of communication, which could result in different departments contacting the same customer for the same purpose.

The flip side Sales force automation has become essential as companies are required to eliminate nonvalue adding manual work, and eliminate delays caused, thus improving the response time to market needs, and capture the data online

Sales force automation has several models and whatever model we use has advantages. The entire system of work becomes extremely channelised and interactive. G Rajasekaran Regional Sales Manager and Product specialist (SE Asia), Hi Media Laboratories Pvt Ltd

The nature of work from the sales managers expects them to be on the field most of the time. Today, the development of smartphones has augmented the growth process of sales force automation much more. Smartphones are easy to carry, easy to use, and have great interface design, touchscreens and fast wireless network abilities like 4G and 3G phones. Today a large number of organisations have deployed mobile sales force automation project and new Smartphone platforms, such as Apple’s iOS and Google’s Android. These indicate a future of increasing diversity in device selecting and support for sales force. When implementing the mobile sales force automation application or during the first stage of systems development life cycle, project teams are required to evaluate how prospective solutions comprising mobile devices, software and support infrastructure and carrier services are packaged to deliver optimal system usability, manageability and integrative abilities, as well as high scalability, reliability and performance. Discussing the future of sales force automation, Chittaranjan avers, “The hype has already been built up. I believe that everyone is giving their best to enhance the benefits derived from automation. However, infrastructure scenario must be worked upon. Today, the trend is for competitive market.” Thus, sales force automation aims to get rid of all the manual errors and bring about an environment of transparency.”


Modern Pharma•1-15 July 2012

24

Tenders

Latest Popular Tenders brought to you by www.tendersinfo.com Centrifuge Org : TRN : Desc : DSLD : BOD : Loc : BT :

Department of Health 11463797 Refrigerated floor standing centrifuge NA 10 July 2012 India Domestic (NCB)

Drugs/Medicines Org : Department of Atomic Energy TRN : 11498888 Desc : Supply of amino acids and vitamin capsules DSLD : NA BOD : 10 July 2012 Loc : India BT : Domestic (NCB)

Spectrophotometer Org : Central Revenues Control Laboratory TRN : 11416265 Desc : Supply, installation and commissioning of gas chromatograph, UV-VIS spectrophotometer, fourier transform infrared spectrophotometer (FTIR), high performance liquid chromatography DSLD : NA BOD : 10 July 2012 Loc : India BT : Global (ICB)

Spectrophotometer Org : Department of revenue TRN : 11431978 Desc : Purchase of atomic absorption spectrophotometer (AAS)

DSLD : BOD : Loc : BT :

NA 10 July 2012 India Domestic (NCB)

TRN : 11505969 Desc : Supply of hydrochlorothiazide tablets DSLD : NA BOD : 11 July 2012 Loc : Sri Lanka BT : Global (ICB)

Spectrophotometer Org : TRN : Desc : DSLD : BOD : Loc : BT :

Department of Revenue 11428825 Purchase of UV-VIS spectrophotometer NA 10 July 2012 India Domestic (NCB)

Spectrophotometer Org : National Institute Of Immunology TRN : 11584962 Desc : Supply of spectrophotometer system & bod incubator DSLD : NA BOD : 11 July 2012 Loc : India BT : Global (ICB)

Spectrophotometer Org : TRN : Desc : DSLD : BOD : Loc : BT :

Dow University of Health Sciences 11604994 Supply of spectrophotometer NA 10 July 2012 Pakistan Global (ICB)

Spectrophotometer Org : TRN : Desc : DSLD : BOD : Loc : BT :

Drugs/medicines Org

: State Pharmaceuticals Corporation of Sri Lanka TRN : 11505968 Desc : Supply of thiamine tablets BP 10mg (Vitamin B1 tablets) or thiamine hydrochloride tablets USP DSLD : NA BOD : 11 July 2012 Loc : Sri Lanka BT : Global (ICB)

Drugs/Medicines Org : Veterinary Services Department TRN : 11518342 Desc : Supply of allopathic medicine, supply of pharmocoepial medicine etc. DSLD : NA BOD : 16 July 2012 Loc : India BT : Domestic (NCB)

Drugs/Medicines Org

Department of Biotechnology 11599271 Supply of spectrophotometer NA 11 July 2012 India Domestic (NCB)

: State Pharmaceuticals Corporation of Sri Lanka

Org: Organisation’s name; TRN: Tendersinfo Ref No; Desc: Description; DSLD: Doc Sale Last Date; BOD: Bid Opening Date; Loc: Location; BT: Bidding Type

INFORMATION COURTESY: TENDERSINFO.COM 1, Arch Gold, Next to MTNL Exchange, Poisar, S.V. Road, Kandivali (W), Mumbai - 400067 Maharashtra, India Tel: +91 22 28666134 • Fax: +91-22-28013817 • Email: parmeet.d@tendersinfo.com

Event List

N AT I O N A L E V E N T S US Georgia-India Life Sciences Opportunities Summit The summit will feature a one-day “howto-with India life sciences” series of speakers, a Business to Business matching (B2B) focus tailored for Atlanta companies in the vaccines and CROs, CMO areas, etc. The event aims to bring decision makers under one roof; August 23, 2012, ITC Maratha, Mumbai For details contact: FDASmart Tel: +91 96196 61452 Email: Rbalani@fdasmart.com

Website: www.fdasmart.com/events/ macoclife

India’s premier industrial trade fair on products and technologies related to Machine Tools, Hydraulics & Pneumatics, Process Machinery & Equipment, Automation Instrumentation, Packaging & Auxiliaries, IT Products, Electrical & Electronics, Material Handling and Safety Equipment.

Annual Pharmacovigilance 2012 The event aims to discuss the latest technologies, methodologies and introducing pharmacy automations on work practices of pharmacovigilance, recent successful strategies and business models to bring out new medicines, keeping abreast of the changes impacting the drug safety industry, etc. Further, there will be discussion on global marketing strategies; August 31, 2012, Hyatt Regency Mumbai

AHMEDABAD

PUNE

CHENNAI

LUDHIANA

INDORE

AURANGABAD

Gujarat, Oct 5-8, 2012

Maharashtra, Nov 2-5, 2012

Tamil Nadu, Nov 22-25, 2012

Punjab, Dec 21-24, 2012

Madhya Pradesh, Jan 11-14, 2013

Maharashtra, Feb 1-4, 2013

RUDRAPUR Uttarakhand, Feb 23-26, 2013

For details Infomedia 18 Ltd

Ruby House, 1st Floor, J K Sawant Marg, Dadar (W), Mumbai 400 028. • Tel: 022 3003 4651 • Fax: 022 3003 4499 • Email: engexpo@infomedia18.in

For details contact: Virtue Insight Tel: +91 44 64536444

Fax: +91 44 64536443 Email: info@virtueinsight.com Website: www.virtueinsight.com

Fax: +91 422 2611043 Email: ijbbb@vip.163.com Website: www.ijbbb.org

the production, characterisation and use of reference standards to exchange their views and opinions on the different issues related to the subject; September 3-4, 2012, EDQM Premises, Strasbourg, France

I N T E R N AT I O N A L E V E N T S JCBBB 2012 The 3rd Journal Conference on Bioscience, Biochemistry and Bioinformatics (JCBBB 2012) aims to provide a forum for researchers, practitioners, and professionals from the industry, academia and government to discourse on research and development, professional practice in bioscience, biochemistry and bioinformatics. This is one of the leading international conferences for presenting novel and fundamental advances in the fields of bioscience, biochemistry

and bioinformatics. It also serves to foster communication among researchers and practitioners working in a wide variety of scientific areas with a common interest in improving bioscience, biochemistry and bioinformatics related techniques; September 1-2, 2012, Phuket, Thailand For details contact: International Journal of Bioscience, Biochemistry and Bioinformatics Tel: +91 422 2611146

International Symposium on Pharmaceutical Reference Standards The event aims to discuss current topics and future approaches related to pharma reference standards. Pharmaceutical reference standards are essential for the quality control of medicines. The symposium will bring together stakeholders involved in

For details contact: EDQM Public Relations Division & Documentation Tel: +33 0 3 88 41 31 50 Fax: +33 0 3 88 41 27 71 Email: beatrice.barth@edqm.eu Website: www.edqm.eu

The information published in this section is as per the details furnished by the respective organiser. In any case, it does not represent the views of Modern Pharma.


Modern Pharma•1-15 July 2012

Event Report

25

Cool Logistics Summit

Cashing in on the growth opportunity in Indian pharma Shibani Shah shibani.shah@infomedia18.in

harma and food industry mainly deal with raw materials, which are temperature sensitive and need to be delivered in potent condition. Slight variation in temperature greatly affects the quality of the material and hence the logistics of such materials need to be monitored diligently to ensure the best quality. A ‘Cool Logistics Summit’ was held at JW Marriott on June 15, 2012, which saw the presence of industry leaders, experts and logistic service providers to seek solutions to maintain & monitor cold chain. It was organised by KamiKaze and saw the participation of various logistics and freight providers as well as giants such as CHEP, Blue Dart, TCI and Renaissance; they also exhibited the latest technologies used by them for temperature-sensitive products.

P

L-R: Upadhyay, Jadhav, Srinivas, Sathya Narayanan

Discussing Indian trends Due to variations in geographical conditions across the country, it is very difficult to transport temperature- and time-dependent pharma products to the remote part of the countries. Also, imported pharma products need to be stored under competent infrastructure that does not hamper the efficacy and quality of the product. There was a panel discussion on ‘Good distribution practices in cold chain logistics & its applicability to the market.’ It included M S Manjunath, Leader - Business Creation, Cold Chain, Ingersoll Rand International (India) Ltd; Subhashis Basu, Head - Dairy Product, Mother Dairy Fruit & Vegetable Pvt Ltd; Nitin Saini, Head - Distribution, Yum! Restaurants India Pvt Ltd; and Ashish Seth, Director- Materials, The Indian Hotels Company Ltd. The discussion concluded with the idea of having freezer on wheels, which will enable the smallest distributors to receive the product at the right temperature. Another

An interactive session at the summit

L-R: Seth, Saini, Basu and Manjunath at the summit

problem highlighted was the inability to store different products together in the same container. Manjunath also highlighted the challenges for the development of cold chain in India.

temperature regulations. The session concluded with Kavita Kulkarni, Technical Support Manager - Food Safety Division, 3M India Ltd, talking on the management of cold supply chain for quality and safety.

Maintaining the lifeline of pharmaceuticals

In-house vs outsourcing

The second session began with a presentation by Hemanth D P, COO - Hub Development, Cargo and Free Trade Zone, GMR Hyderabad International Airport Ltd, on cold chain integrity lifeline of life sciences in which he briefed about the state-ofthe-art facilities available for pharma logistic products. This was followed with a presentation by Surendra Deodhar, Head - Material Management, Reliance Life Sciences Pvt Ltd, who suggested the development of reefer vans with compartments having different temperatures for the transportation of small volume biopharma products that need to be stored under stringent

Rajiv Goyal, Senior GM – Frozen Foods, Hatsun Agro Product Ltd spoke on in-house v/s outsourcing involved in cold chain management. His presentation highlighted the benefits and shortcomings of both in house distribution and outsourcing. He suggested that in house and outsource together make business successful. Rajesh Vij, GM - Import and Exports, Wockhardt Ltd, in his presentation explained the parameters that need to be kept in mind while selecting the logistics provider. He also suggested that the third party logistics (3PL) strategy saves about 3 per cent of the total cost. The third panel discussion was on ‘The overall investment outlook via the PE Route for Cold Chain Infrastructure & Distribution Development in India.’ The panel included Suneel Aiyer, Partner, LeapRidge; Ajay Garg, Founder and MD, Equirus Capital Pvt

With an aim to share knowledge and understand the various parameters such as temperature-controlled packaging, infrastructure, transportation and logistics strategies involved in cold chain management, a one-day Cool Logistics Summit was recently held in Mumbai. Ltd; and Nitin Nayar, Principal, Warburg Pincus Pvt Ltd. The experts looked into the large investment that goes into the infrastructure for cold storage. Some experts highlighted how the transportation of products to different locations involve different packaging standards and facilities. Geographical diversity is an important factor while deciding on the different parameters of logistics. The last session of the summit had a panel discussion on ‘Assessing new technologies, innovations & solutions available in the market to ensure optimal end-to-end cold chain management.’ The panelist were Vikas Upadhyay, GM- Commercial Refrigeration, Carrier India; Ramdas Jadhav, Manager - Order Fulfillment & Customer Service Supply Chain, Thermo Fisher; and K Srinivas, GM, Arshiya International Ltd and K D Sathya Narayanan, GM-Materials Management, Manipal Hospital. During the summit the experts felt a need to educate the handlers involved in the transport process. When asked about standardising the transportation of pharma products in particular Jadhav added that there can be some basic standards but no thumb rule since there is a lot of variation in the products and the standards differ from company to company. The few take aways for the day were to choose rail over roadways which prove to be more economical

It is better to choose rail over roadways as it proves to be more economical. Further, geo fencing can be applied to keep a tab on the transport container. and geo fencing can be applied that will enable the manufacturer to keep a tab on the transport container. The various logistics providers were also a part of the summit. The giants CHEP, Blue Dart, TCI and Renaissance displayed the latest technologies used by them for temperature-sensitive products. It also gave a good opportunity to the logistic providers and the company experts to network. The industry leaders looked into the queries of the logistics service providers to work collectively and ensure proper distribution of the products.


Modern Pharma•1-15 July 2012

26

Book Review Editors: Deepak Thassu, Michel Deleers, Yashwant Pathak

Nanoparticulate Drug Delivery Systems The editors-all renowned in the field of pharmaceutical technology development have put together a comprehensive multi-author guide to the application of nanotechnology in pharmaceutical industry. The book focusses on the wide gamut of applications of nanoparticulate drug delivery systems for betterment of the healthcare. Chapters 1 to 6 delineate the various drug delivery systems available for utilisation by the drug industry including nanoparticles, nanosuspensions, liposomal drug delivery systems, nanocrystals and nanofibres. Chapters 7 to 10 deal with the bioengineering of these drug delivery systems, the challenges and the application of new technology for the mass synthesis of these systems. The next couple of chapters dedicated to the rise of nanomedicine and the qualities of a potential nanoagent make for an inspirational reading. Chapters 13 to 21 explore the wider application of nanodrug delivery systems in various streams of medicine from cosmetology, ophthalmology, gene therapy, vaccines, transdermal patches, and others. The book is a good overview of the past, present and future of nanomedicine. It is fairly technical and requires a certain degree of understanding and knowledge of chemical manufacturing, polymer technology, formulation and nanomechnaics to fully appreciate the wealth of information in this book. A must read for all R&D staff and drug developers willing to foray into nanomedicine.

Editors: Issac Ghebre – Sellassie Charles Martin Price:

` 3995/-

Publisher: Informa Healthcare Distributor: Wisdom Book Distributors, Hornby Building, 1st Floor, 174, D N Road, Mumbai 400 001, Tel: 022 2207 4484/6631 8958, Telefax: 022-2203 4058 Email: thadam@vsnl.com

` 4995/-

Price:

Publisher: Informa Healthcare Distributor: Wisdom Book Distributors, Hornby Building, 1st Floor, 174, D N Road, Mumbai 400 001, Tel: 022 2207 4484/6631 8958, Telefax: 022-2203 4058 Email: thadam@vsnl.com

Pharmaceutical Extrusion Technology For engineers in love with machines and technology, this is a one-stop solution for all that is part of the pharmaceutical extrusion process. The editors have brilliantly managed to mix and put forth all about pharmaceutical extrusion process in a very simple language. The book starts by giving an overview of the extrusion process, technology, history and the need for the application in the drug industry. The next few chapters dwell into the details of the various types of extruders available from single screw, twin screw, different rotator mechanisms, etc. The chapters are well illustrated with both diagrams and actual photographs making the description simpler to understand and visualise. The chapters dedicated to dies and feeder technology bring about the importance to the respective parts in the entire process of extrusion. The latter half of the book details different applications of the extrusion process and technology to produce pellets, controlled dosage forms, laminates, sheets, etc. The recent advances have been described in chapters 15 and 16 dealing with spheronisation and wet granulation. The book concludes with comprehensive discussion regarding installation of the machinery and monitoring of the processes and quality control. The last chapter emphasises the growing importance of the extrusion processes in modern pharmaceutical manufacturing and regulatory landscape. This is a machinery and mechanics intensive book, but one which should not be missed by anyone from the manufacturing industry.

Reviewer: Dr Mandar Kubal, Consultant - Infectious Diseases and HIV AIDS, Infectious Diseases and Pulmonary Care (IDPC)

An

invite that

1-15 July 2012 I Vol 1 I No 1 I `100

rewards as well...

Scan this code on your smart phone to visit www.mph online.in

CEO Roundtab

le 15

Future trends in the Indian pharma industr and the role of media to y bridge the need gap

Venus gets for antibioticUS patent drug VENU

Alembic settle s patent case with Novar tis

You can send us Technical Articles, Case Studies and Product Write-ups. The length of the article should not exceed 1,200 words, while that of a product write-up should not exceed 100 words.

tion With

17

ALEMBIC Pharmaceutic with Brecke als along nridge (US), has settled Pharmaceutical a patent case Novartis for with rivastigmine capsules used tartrate for treating The compa dementia. nies have settled Paragraph IV patent litigati their Novartis for on with rivastigmine capsules, tartrate a generic version of Exelon capsul es of Novar tis.

s 18

Recent advance s in the pharma cold chain The need to get tech-sav vy

Insight & Outlo

ok 22

Sales force automa Say ‘no’ to manual tion errors

Waters to ex

pand in Indi

a

Ireland attr

the near future. The expansion phase II woould be of at Ahmed and Chand abad igarh. Besides expans ion Waters partne ring is also with pharm aceutic companies, al CROs and agencies with government research capabil the goal of expand ing ities, increas efficiency, ing laboratory and naviga regulatory ting comple compliance x worldwide. requirements Waters with Dr Reddy’ has recent partner ed s Laboratories, Therapeutic Lambda Research Ltd, Agricultural Product Export the Marine/ Agency and Development the India Protection Environmenta Agency. l

acts Indian

- Jasleen Kaur Batra

pharma

FOR pharm aceuticals, EU marke the the t is going throug EU region has typical an inflection h charac teristics of small manuf such as MSD,point. MNCs Germa operating. acturing base, ny is a could help Johnson Irish Govern Johnson, tender ment is highly Pfizer, Abbot& driven, where radical benefiin achieving proact as France Lilly, Roche t, is an ive, busine of expediting ts in terms and ss friendly Teva, Taked , Novar tis, driven innovators drugan a, Genzy strategy by go-to-market Ireland astute visionary. Allergan, me, a backgrmarket. With such 40 per cent, has Gilead, Astella reducing costs best highly some of the Bristol-Myer s, absolu ound, it becomes of inventory.” Positive skilled talent. s Squibb tely essent The prosp It has a Glaxo and ial ects Smith Japanese pharm for sector Irish life sciences standard, Kline is about appro ved EU have established a industry for THE prospe 45 billion their footho cts tax rate of corpo ration in Ireland ld market over for Japan’s pharma . Besides, 12.5 Indian on all tradin per cent the mediu companies are very such as Relian g profits positive, said m term Additionally Life . ce Scienc by Resear a report , Ireland es and Ranba ch an excelle has have a country has and Markets. The nt strong presen xy double taxatio network of too. K V ce pensi onabl one of the largest Subramaniam n avoidance e treaty with Presid ent , popul ations healthcare 55 countries , is readily CEO, the world in Reliance Life and the accessi includ Sciences, said, ble, govern ing India. Recognising “Reliance appreciates investment ment Life Scienc this, the Irish in biomedical es Pvt Government Ltd, India, and the research had acquir place a nationhas put in GeneMedix ed balances the regulatory regime plc, al Strateg requirements for Scienc biotechnology a UK-based Subram y major stakeh e, of the aniam olders. and Innova Technology 2007. This company in tion (SSTI) Batra provided the 1990s. with an GSK to buy In line with in opportunity us Indian pharm this, a companies signifi cant enter to to have Toctino for eczema drug the fundin g (mainl Europ ean an on-gro £ and support are biopharma und While y export oriented). EU presen GLAXOSMIT 146 million available to market.” ce in order innovation fuel the EU Minakshi to expand hasannounce HKLINE Plc (GSK) across indust pharma Batra, India market into the d that it research Director, territories. eczema drug EU billion is worth $ 48 is buying and educat ry, India An Ireland, Toctino from , $ 16 billion ion. Additionally said, “Each presence either on-ground the Pharmaceutic Basilea , there is is for 25 country generics, a in terms of a in sales per £ 146 million Ltd, for an initial and marke huge oppor presenting provid cent tax credit ($ 227 million ting or a ed to organi Toctino is India. Batra tunitie s for for ). the only R&D & innova sations prescription said, “The medic ine tion.” appro ved treatm ent - Chandreyee for the Bhaumik of severe QUINTILES hand eczem chron ic recently a agreements announced potent topica unresponsive to to of the l regional headquestablish a Quinti It is comm steroids in adults. les Gilling New Health,” said arters ercially availab Dennis s, CBE, Execut for China Shanghai and 14 countr in China le in in Quint ive Chairm ies, approv , Quintiles iles, “By lab testing to significantly expand an, $ 14 ed in 15 countries, is investi broade capabilities million to investment and is in ng “With its in China. a phase III and infrast ning our 4000-s establish trial in the burgeo a new quare-metre ructure here, Quintiles US. growing healthc ning economy and is ready to (43,00 feet) headqu partner with our biopha arters in Shangh 0 square billion citizen are needs for its rma custom China and 1.3 look s, China ers as nearby Asian ai to serve to realise the oppor China’s potent they “This demon tunities and exemplifies To countries. strates our provid e ial.” to challenges the infrast commitment this district essential and to for its growth ructur e Ling Zhen, Gener China,” said strategy al Manag Quintiles’ er, operations in China.

Quintiles de

epens inves

The articles should preferably reach us in soft copy (either E-mail or a CD). The text should be in MS Word format and images in 300 DPI resolution & JPG format.

Special Focu

Indravadan Modi Chairman, Cadila Pharma ceuticals Ltd

S Remedies has receive patent from d the its new antibio US Patent Office for WATERS targets drug tic product, which India, one of the leadin analytical The produc resistant infections. companies g t, CSE 1034, under the is curren found to has been tly process of be its facility wide range effective against a in Bengaluru. expanding facility is “The new drug resista of likely to have nt set of labora an infections, tories, upgrad improved facilities and ed trainin includ ing g more office the completed, space. When ‘superbugs’. the new facility will approximatel Mufti be y Suhai l floor space,” 16,000 square feet Sayee d, in inform Vice ed Art Caput President, President, Water o, Inc. To expand s Division, Water Sayeed Venus Medic s the existin al at Peenya g facility Research , Bengaluru, Centre has investe the compa patent of CSE , said, “The US d an ny of ` 2 million approximate amoun development 1034 is a landmark t . Besides this, for initiat in Mumb the labs process of ing the ai, Delhi commerciali and Hyder will also this novel sation of abad undergo an drug.” Caputo expansion in

Dear Reader, ‘Modern Pharma’ solicits original, well-written, application-oriented, unpublished articles that reflect your valuable experience and expertise in the pharmaceutical industry.

In Conversa

tment in Ch

ina

The final decision regarding the selection and publication of the articles shall rest solely with ‘Modern Pharma’. Authors whose articles are published will be sent a complimentary copy of that particular edition. Published by Infomedia 18 Ltd, ‘Modern Pharma’ is one of the leading fortnightly magazines exclusively meant for producers and user fraternities of the pharmaceutical industry. Well supported by a national readership of over 80,000 and our strong network of 26 branch offices across India, this magazine reaches out to key decision makers among the Indian manufacturers of pharma products, machinery and allied sectors. Brought out in association with Hong Kong-based Ringier Trade Media Ltd (one of the world’s largest trade publishing houses with more than 200 special interest titles and offices in every major country), it ensures that advertisers are able to promote their products and services across the globe at no extra cost. So get going and rush your articles, write-ups, etc… Thanking you, Yours sincerely, Manas Bastia Senior Editor Infomedia 18 Limited ‘A’ Wing, Ruby House, J K Sawant Marg, Dadar (W) Mumbai 400 028 India

D +91 22 3003 4669 T +91 22 3024 5000 F +91 22 3003 4499 E manas@infomedia18.in W www.infomedia18.in


Modern Pharma•1-15 July 2012

Products Metal analyser The 7700 series ICP-MS metal analyser is productive, simple-to-use, high sensitivity, low background, better interference removal, increased flexibility, easier to maintain and service. This workhorse 7700x is used for most applications, and in high-throughput commercial labs. It is designed specifically for semiconductor applications. The new 7700e offers a simplified and easy-to-use system for routine analysis. Featuring a new, configurable MassHunter software platform and a host of hardware developments, including a new frequency-matching RF generator and 3rd generation Octopole Reaction System (ORS3), all three 7700 series mainframes provide unrivalled levels of performance and ease-of-use. Agilent Technologies India Pvt Ltd New Delhi Tel: 011-51496664 Email: agilent@agilent.com Website: www.agilent.co.in

Laboratory chillers Polystat® Laboratory Chillers has quick rampup and cool-down with all operational and preventive maintenance accessed through the front panel. Designed to provide temperature control with the flexibility needed for demanding applications, they fit comfortably on a laboratory bench top. These chillers feature a temperature range of -10 to 80°C. The chillers allows the user to choose between five temperature set points. The air-cooled refrigeration system eliminates need for external water source and the small internal reservoir limits evaporation. With built-in energysaving mode, this series provides an environmentally friendly option for any laboratory. This mode activates a responsive control that will allow the chillers to operate with minimal energy consumption Cole-Parmer India Mumbai - Maharashtra Tel: 022-6716 2222 Email: vinita.singh@coleparmer.in Website: www.coleparmer.in

Adapplicator system developed by Braun, the spray alternative to needle injection, are few examples. Neejtech India Ahmedabad - Gujarat Tel: 079-26561312 Mob: 09825040231 Email: info@neejtech.com Website: www.neejtech.com

Steam boiler The fully automatic package steam boiler (IBR) has capacity ranging from 100 kg/hr to 2000 kg/hr with operating pressure of 10 kg/cm² g. Smoke tube & water tube version is also available. Coil is made from seamless tube of asthma 106 GR-B pipes. The unit is equipped with high efficiency oil/gas burner with air pre-heater arrangement which gives high thermal efficiency. Aero Therm Systems Pvt Ltd Ahmedabad - Gujarat Tel: 079-25890158 Email: contact@aerothermsystem.com Website: www.aerothermsystem.com

Pharma inspection machine The paper folding, shrink pack and pharma inspection machines are tested for CE marking, and thus fulfill one of the major statutory requirements of European Union. A range of customised solutions as per pharma industry requirements is also offered. Pharma inspection solutions include: pharmacode readers, leaflets and cartons. These have been specially designed for online checking of pharma codes printed on tubes, cartons, leaflets, labels, etc. Pratham Technologies Pvt Ltd Pune - Maharashtra Tel: 020-24352624 Mob: 09822047399 Email: enquiry@prathamtech.com Website: www.prathamtech.com

filtration, and environmental monitoring. Advantec’s range of filtration products fits comfortably within Cole-Parmer’s own product range. It offers customers an additional and valuable range of unique quality products that will enhance their processes and research. Cole-Parmer India Mumbai - Maharashtra Tel: 022-67162222 Email: vinita.singh@coleparmer.in Website: www.coleparmer.in

Capsule filling machine These automatic capsule filling machines also known as encapsulation equipment are compact, sturdy, covered with stainless steel panels, and hood covered with acrylic guard. The fill weight adjustment takes place within seconds. These machines are provided with tamping mechanism for powder filling, which enables capsules to be filled with a weight variation with ±2 per cent. Anchor Mark Pvt Ltd Mumbai – Maharashtra Tel: 022-28682001 Email: sales@anchormark.com Website: www.anchormark.com

Sieves

These are silicon moulded sifter sieves, fluid bed dryer (FBD) sieves and FBE dryer sieves. The silicon moulded sifter sieves are available in various sizes from 12” to 48” diameter. These are available in rivetted and special non-rivetted design. The mesh sizes vary from 4 mesh to 500 mesh with ASTM & BSS Standards. Atlanto Enterprises Mumbai – Maharashtra Tel: 022-23096098 Mob: 09819942853 Email: atlantoent@yahoo.co.in Website: www.atlanto.net

Filtration and separation products Rotary vane vacuum pump

Cleanroom moulds

Adapplicator, Alu cap, Snap cap, PE bottle pack cap, PE twin port cap are only some of many cleanroom moulds from Braunform. Highly sensitive packaging and measuring components, caps for use in dental and insulin fields, dialysis components, hygiene products and the

Advantec’s wide range of filtration solutions are used for laboratory, research and process applications. These products are used in a wide variety of scientific capacities and applications, such as microbiological analysis, air/gas

The Minivac SVL series of low vacuum pump is a sliding vane-type direct/ belt-driven vacuum pump mounted on common base frames. It is compact in size, vibration-free and hence can also be mounted inside the machine. The pump attains maximum vacuum levels up to 29” of Hg with capacities ranging

27

from 50-2000 lpm. Unique design of the lubrication system positively feeds minimum required oil to all rotating and frictional parts. The pump is useful in applications like capsule filling/ capsule printing machines and other pharmaceutical machineries, packaging/ labeling machines, screen printing/plate making, book binding/folding machines, vacuum chucking, etc. Shree Siddhivinayak Industries Dist Thane - Maharashtra Tel: 022-28458372 Email: minivac@rediffmail.com Website: www.minivacpumps.com

Shaking incubator

The compact benchtop Stuart SI500 and SI505 shaking incubators have a unique retractable platform providing easy access to samples, a digital display showing the independently controlled temperature and speed, and USB connectivity for long-term monitoring of the incubator temperature via a PC. Removable water reservoirs increase the humidity in the chamber of the Stuart SI505, dramatically reducing sample evaporation. The Stuart SI500 incorporates a versatile clamping system for securing flasks of most sizes, while angle-adjustable stainless steel accessory tube racks with magnetic locking system providing quick coupling and de-coupling. Bibby Scientific Ltd Staffordshire - UK Tel: +44-1785-812121 Email: info@bibby-scientific.com Website: www.bibby-scientific.com

Walk-in humidity chamber The unit has double-walled insulated PUF modular panels, which can be easily assembled at site. Interior is made of stainless steel and exterior is either made of mild steel finished with powder coating or stainless steel. The unit has full-length inner glass door and outside metal door with magnetic gasket and lock. It is provided with perforated stainless steel trays and has forced air circulation for uniform temperature. The intelligent controlling system has PLC base and PC communication. It has long lasting stainless steel tubular heaters with SS fins. Newtronic Equipment Company Pvt Ltd Mumbai - Maharashtra Tel: 022-28679326, Mob: 09821089932 Email: nmehta@newtronic.in Website: www.newtronic.in

Looking For A Specific Product? Searching and sourcing products were never so easy. Just type MPH (space) Product Name and send it to 51818 eg, MPH Laboratory software and send it to 51818


Modern Pharma•1-15 July 2012

28

Products

Fluid control systems

A wide range of precision fluid control systems, like pneumatically operated air pulse dispensers, and allied accessories, such as tips barrels, precision dispense valves (for various applications) pressure tanks, etc, are offered to give a positive control for handling various fluids. Dotting, lining, potting, filling, doming, encapsulating, spraying, coating, etc can be done with ease, efficiency and high degree of repeatability and accuracy. These systems handle any type of fluids like adhesives, anaerobics, light curing, UV curing, moisture curing (cyanoacrylates), latex based, solvent based, etc coating fluids (hard coating of optical lenses), lacquers, dyes, etc. Metering & Dispensing Technologies Dist Thane - Maharashtra Tel: 022-28042189, Mob: 09833783720 Email: amritwalimbe@gmail.com

Magnetic drive centrifugal pump Lutz magnetic drive centrifugal pump is available in two series range AM and TMR. The materials are in glass-filled PP or carbonfilled ETFE. Unique feature of the TMR series is that the pump can run dry for up to 15 mins without damage. The inlet/outlet for the pump is offered in threaded (BSP/NPT) or flanged (ISO/ ANSI) connections. The TMR series is disassembled without disturbing the motor. Maximum flow rate that achieved is up to 30 m³/hr and heads up to 25 mWc. The strong magnetic coupling made up of rare earth materials and three versions of each model allow pumping of liquids of special gravities from 1.00 to 1.85. Shanbhag & Associates Mumbai - Maharashtra Tel: 022-28346604 Email: shanbhags@vsnl.com Website: www.shanbhags.com

Electronic panel timer The electronic panel timer is housed in small industrial grade plastic box. It gives 5 per cent setting accuracy and 1 per cent repeat accuracy. It is available in 415 V or 230 V with one changeover contact. Timing range is 30 sec, 60 sec, and 120 sec. Power and delay indications are provided on the front side of the timer. Potentiometer is provided to set the required time. It measures 102 mm x 65 mm x 43 mm and weighs 250 gm approximately. Gelco Electronics Pvt Ltd Ahmedabad - Gujarat Tel: 079-22200902 Email: info@gelco-world.com Website: www.gelco-world.com

Pallets

These pallets are offered as per GMP & USFDA norms and are used for multifarious applications in different industries. Designed for optimal load bearing capacities, the pallets are manufactured on state-of-the-art plants. The pallets have many outstanding features and can also be tailor-made to meet customers’ special requirements. Sintex Industries Ltd Kalol - Gujarat Tel: 02764-253500 Email: icontainers@sintex.co.in Website: www.sintex-plastics.com

Bottom discharge centrifuge This centrifuge is fitted with a cake scrapping arrangement, which can be motorised or hydraulically operated to enable to scrape the stickiest of cakes. The cake is discharged through the bottom chute provided. This results in reducing manual labour, less cake handling loss and uniform cake washing. The centrifuge is offered in vapour-tight construction with nitrogen blanketing for hazardous chemicals. CIP design with builtin cleaning nozzles ensures no product crosscontamination. The centrifuge is offered in three-point pendulum suspension and fourpoint inertia plate mounted designs to suit application considerations. United Engineering Enterprises Mumbai - Maharashtra Tel: 022-23083990, Mob: 09820761808 Email: uenggent@gmail.com Website: www.united-centrifuges.com

Blister packing machine The model PBM140C high-speed mass production blister packing machine is designed to pack all types of capsules, tablets, soft gels, injection solution, syringe and other small laboratory or hospital preparation products. It packs small products in different types of clamp shell packages. It is widely used in pharmaceutical, herbal, food and other related industries. It is also suitable for packing with aluminum/PVC, paper/ plastic laminated materials. This machine consists of aluminum foil automatic feeding, upper and lower cobweb male and female joining, multi-stage cylinder heat sealing, automatic indenting, batch number printing and aluminium alloy double heating. Advanced Liquid Packaging Arizona - USA Tel: +1-602 -4900220 Email: sales@induction-sealers.com

Pharmaceutical medicines A wide assortment of pharmaceutical medicines that are known for their effective results are offered. Made in proper hygienic conditions, these medicines are categorised into topical, oro-dental, gynaec & haemostats, intravenous fluids, anti-allergic, cold

Fluid bed dryer

& cough medicines, antibiotics & quinolones & cephalosporins, antacids, anti-ulcerants & laxatives and appetite stimulants enzymes. Schwitz Biotech Ahmedabad – Gujarat Tel: 079-27493057 Mob: 09825374233 Email: schwitz_rkb@rediffmail.com Website: www.schwitzbiotech.com

Conductivity meter The mhoCounter CT-10 is a conductivity indicator and mhoCounter CT-11 is the meter with relay output option, which is programmable. Microprocessor-based electronics allow wide operating range and long term signal stability. Optional relays provide control for adjustment or alarms. These meters come with saddle mounting option or standard fittings to adopt to any process flow solution. Vatturkar Industrial Pune – Maharashtra Tel: 020-25380568 Mob: 09422320551 Email: response@vatsmeter.com Website: www.vatsmeter.com

Multi-purpose trolley The specially designed multi-purpose trolley is used for ICU/ hospital/surgery. It comes with multipurpose aluminum extruded legs, heavyduty designed castor wheels, MDF monitor top with anti-skid rubber mat, lockable MDF, scratch-proof painted drawer box. Different boxes or trays are adjusted according to needs due to the specially designed profile of tapped strip. Because of aluminium metallic structure, earthing is affirmative and provides safe working for electrical and electronic appliances. Envair Electrodyne Ltd Pune - Maharashtra Tel: 020-30688117 Email: envairelectro@vsnl.net Website: www.envairelectrodyne.com

Filling & capping machine Steril 400 filling and capping machines are meant for sterile applications in the pharmaceutical industry. These machines can be installed under an isolator. The machines consist of three modules and are suitable for different layout requirements. These machines are completely accessible from the front and are protected by laminar flow recycling. Marchesini Group Bologna – Italy Tel: +39-51-6518711 Email: sales@marchesini.com Website: www.marchesini.com

This dryer is used for drying of wet material. It is equipped with air handling unit. The inlet air filtration is through pre, micro vee and hepa filter. It performs uniform and harmonious drying operation in a specified time. It has applications in tablet-granulation section of pharma industries. This dryer is compliant with cGMP under WHO and USFDA. Also offered is diversified novel advanced techno-upgraded qualitative model of fluid bed dryer like PLC operated, semi-automated and manually operated dryer with multi faceted and user-friendly features. Ratnakar Pharma Machinery Ahmedabad - Gujarat Tel: 079-22892614, Mob: 094270 31284 Email: ratnapd@yahoo.co.in Website: www.ratnakarpharmamachinery.com

Temperature data logger The data logger for pharmaceutical industries has measuring capacity ranging from -35-80°C, accuracy of ±0.5°C and resolution of 0.1°C with sensor Pt1000. The measuring rate is selected from 1 min to 8 hours. It can store 4,000 value data in memory. The measuring mode is automatic with loop, start/stop or start with set measuring rate. It comes with a battery life of 3-5 years. The data logger is housed in stainless steel, PEEK. It has IP68 protection class/ housing for pharmaceutical industries. Ambetronics Mumbai - Maharashtra Tel: 022-28371086 Email: ambetronics@vsnl.com Website: www.ambetronics.com

Air-cooled single-stage pump The oillubricated air-cooled sing le-stage pump comes with multivane built-in anti-suck back system. It is provided with oil recirculation system having exhaust filters to produce mist-free exhaust. The pump is available with capacities ranging from 15 m³/hr to 150 m³/hr. The pump is used in various applications like packaging, bottle filling, pick and place, leak detection, heat treatment, distillation, suction in hospitals, oil purification, degassing and drying, etc. Advantages of the pump are less oil, less power, noise less and pollution free compared to normal oil seal vacuum pumps. Toshniwal Instruments (Madras) Pvt Ltd Chennai - Tamil Nadu Tel: 044-26252716 Email: sales@toshniwal.net Website: www.toshniwal.net

The information published in this section is as per the details furnished by the respective manufacturer/distributor. In any case, it does not represent the views of

Modern Pharma


Modern Pharma•1-15 July 2012

Marketplace

29


Modern Pharma•1-15 July 2012

30 List of Products & Advertisers Looking For A Specific Product? Searching and sourcing products were never so easy. Just type MPH (space) Product Name and send it to 51818 eg, MPH Laboratory software and send it to 51818 Product

Pg No

Agitators ........................................................FIC Air-cooled single-stage pump .........................28 Analytical instrumentation........................... BIC Analytical instruments .......................................3 Batch disperser .............................................FIC Blister packing machine...................................28 Bottom discharge centrifuge ...........................28 Bulk bag filler ....................................................29 Calorimeters..................................................FIC Capsule filling machine ..................................27 Centrifugal monoblock....................................29 Chromatography.................................................3 Clamp .................................................................29 Cleanroom moulds...........................................27 COD analyser ....................................................29 Columns...............................................................3 Columns & chemistries ................................ BIC Compact pneumatic cylinder.........................BC Conductivity meter ..........................................28 Disperser........................................................FIC Dry vacuum pump...........................................29 Electric actuator & gripper ..........................BC Electronic panel timer......................................28 Elemental analysis...............................................3 Empower......................................................... BIC Filling and capping machine ........................ 28 Filtration and separation products.................27 Fixtures...............................................................29 Fluid bed dryer .................................................28

Product

Pg No

Fluid control systems .......................................28 Gas detectors ................................................... 29 Grip pliers ..........................................................29 Guided compact pneumatic cylinder............BC Heating bath .................................................FIC High pressure homogenizer ..........................FIC Horizontal handle clamp .................................29 Hot plate ..........................................................FIC HPLC............................................................3,BIC Informatics ................................................... BIC Inline disperser................................................FIC Ionizer ...............................................................BC Jigs ................................................................... 29 Kneading machine .......................................FIC Laboratory chillers ......................................... 27 Laboratory reactor ..........................................FIC Laboratory software........................................FIC Large diameter welded pipes...........................29 Machines and plants for dry and wet preparation ............................................ 11 Magnetic drive centrifugal pump ...................28 Magnetic stirrer...............................................FIC Mass spectroscopy ..............................................3 Metal analyser ...................................................27 Mill ...................................................................FIC Molecular spectroscopy .....................................3 Monoblock high vacuum pump ....................29 Mrfrs of thermoplastic valves & piping system from polypropline ...............................7

Product

Pg No

Multi-purpose trolley .......................................28 Oil seal high vacuum pump.......................... 29 Overhead stirrer ..............................................FIC Pallets ............................................................... 28 Pharma inspection machine ...........................27 Pharmaceutical medicines ..............................28 Pilot plant ........................................................FIC Precision fabrication work...............................29 Pull action..........................................................29 Pump ..................................................................29 Rapid endotoxin detection system............... 29 Refrigerated compressed air dryer.................BC Roots vacuum pump........................................29 Rotary evaporator ...........................................FIC Rotary gear ........................................................29 Rotary lobe pump ............................................29 Rotary pump .....................................................29 Rotary vane vacuum pump.............................27 Sanitary centrifugal........................................ 29 Screw pump.......................................................29 Seals ....................................................................29 Seamless pipes ...................................................29 Self priming monoblock..................................29 Sensors ...............................................................13 Shaker ...............................................................FIC Shaking incubator.............................................27 Sieves ..................................................................27 Silicone FBD gaskets.........................................29 Silicone rubber braided hose ..........................29

Product

Pg No

Silicone rubber compound..............................29 Silicone rubber corona teater sleeve ...............29 Silicone rubber extruded gasket & profile.....29 Silicone rubber tubing .....................................29 Single stage monoblock vacuum pump ........29 Single stage vacuum pump .............................29 Solid-liquid mixer ...........................................FIC Stainless steel pipes ...........................................29 Steam boilers .....................................................27 Straight line action ...........................................29 Submersible .......................................................29 Tefzel HHS isotactic P.P material ................... 7 Temperature data logger ..................................28 Thermostat & vaccum dryer / mixer ...........FIC Toggle action clamp .........................................29 Toggle press .......................................................29 Tradeshow organizer ........................................29 Triplex plunger ..................................................29 Tubes ..................................................................29 Two stage vacuum pump ................................29 ‘U’ tubes ........................................................... 29 UHPLC ................................................................3 UPLC ............................................................... BIC Vacuum conveyor ........................................... 29 Vacuum pump ..................................................29 Vertical handle clamp.......................................29 Vertical inline ....................................................29 Walk-in humidity chamber........................... 27 Welded pipes .....................................................29

BC-Back cover, BIC-Back inside cover, FIC-Front inside cover

Advertiser’s Name & Contact Details

Chamunda Equipments

Pg No

29

Advertiser’s Name & Contact Details

Ika India Private Limited

T: 91-79-27522437

T: +91-80-26253900

E: clamp@chamundaequip.com

E: process@ika.in

W: www.chamundaequip.com

W: www.ika.in

Pg No

FIC

Advertiser’s Name & Contact Details

Pg No

Suraj Limited

29

T: +91-79-27540720 E: suraj@surajgroup.com W: www.surajgroup.com

Charles River

29

Joyam Engineers & Consultants Pvt Ltd

T: +91-80 - 25588175

T: +91-79-26569533

E: india.customercare@crl.com

E: joyam@joyamvactech.com

W: www.criver.com

W: www.joyamvactech.com

Suzhou Glory Exhibitions Co., Ltd. 29

29

T: 86-512-6280-4819 E: crtimes@vip.163.com W: www.cleanroomshow.com Thermo Fisher Scientific Sid Division

3

T: +91-22-67429494 Cognex Sensors India Pvt Ltd

13

Netzsch Technologies India Pvt Ltd

11

E: pradeep.kumar@thermofisher.com

T: +91-020-40147840

T: +91-044-42965121

W: www.thermofisher.com

E: sales.in@cognex.com

E: anton.benjamin@nti.netzsch.com

Uniphos Envirotronic Pvt Ltd

W: www.cognex.com

W: www.netzsch-grinding.com/pharma

29

T: +91-22-6123500 E: singhrv@unipos.com

Dev Engineers

29

Reynders Label Printing India Pvt Ltd

BC

W: www.uniphos-she.com

T: +91-79-26403839

T: +91 149 3305400

UNP Polyvalves India Pvt Ltd

E: info@devpumps.com

E: india@reynders.com

T: +91-265-2649248

W: www.devpumps.com

W: www.reynders.com

E: mktg@polyvalve.com

7

W: www.polyvalve.com Hapman India

29

Shende Sales Corporation

29 Waters (India) Private Limited

T: +91-265-2517505

T: +91-020-24488005

E: info@hapman.in

E: shende@shendesales.com

E: waters_india@waters.com

W: www.hapman.in

W: www.shendesales.com

W: www.waters.com

BC-Back cover, BIC-Back inside cover, FIC-Front inside cover

BIC

T: +91-80-28371900

Our consistent advertisers


RNI No: MAHENG / 2008 / 27125, Postal Regd No: G / NMD / 122 / 2011 - 13, Posted at P.C Stg. OfďŹ ce, GPO, Mumbai 400 001 On 19th & 20th Of Every Month, Date Of Publication: 16th Of Every Month


Modern Pharmaceuticals - 1-15 July 2012